500 
•HRES 1099 EH 
‘‘(d) FEDERAL SHARE.—Notwithstanding any provision 
of law limiting the Federal share under any other Federal 
program, amounts made available to carry out this section 
may be used to increase that Federal share, as the Appa-
lachian Regional Commission determines to be appropriate.’’. 
(b) CLERICAL AMENDMENT.—The analysis for chapter 
145 of title 40, United States Code, is amended by inserting 
after the item relating to section 14509 the following: 
‘‘14510. Drug abuse mitigation initiative.’’. 
Subtitle F—Pilot Program to Help In-
dividuals in Recovery From a Sub-
stance 
Use 
Disorder 
Become 
Stably Housed 
SEC. 8071. PILOT PROGRAM TO HELP INDIVIDUALS IN RECOV-
ERY FROM A SUBSTANCE USE DISORDER BECOME 
STABLY HOUSED. 
(a) AUTHORIZATION OF APPROPRIATIONS.—There is au-
thorized to be appropriated under this section such sums as 
may be necessary for each of fiscal years 2019 through 2023 
for assistance to States to provide individuals in recovery 
from a substance use disorder stable, temporary housing for 
a period of not more than 2 years or until the individual se-
cures permanent housing, whichever is earlier. 
(b) ALLOCATION OF APPROPRIATED AMOUNTS.— 
(1) IN
GENERAL.—The amounts appropriated or 
otherwise made available to States under this section
501 
•HRES 1099 EH 
shall be allocated based on a funding formula established 
by the Secretary of Housing and Urban Development 
(referred to in this section as the ‘‘Secretary’’) not later 
than 60 days after the date of enactment of this Act. 
(2) CRITERIA.— 
(A) IN
GENERAL.—The funding formula re-
quired under paragraph (1) shall ensure that any 
amounts appropriated or otherwise made available 
under this section are allocated to States with an 
age-adjusted rate of drug overdose deaths that is 
above the national overdose mortality rate, accord-
ing to the Centers for Disease Control and Preven-
tion. 
(B) PRIORITY.— 
(i) IN
GENERAL.—Among such States, 
priority shall be given to States with the great-
est need, as such need is determined by the 
Secretary based on the following factors, and 
weighting such factors as described in clause 
(ii): 
(I) The highest average rates of un-
employment based on data provided by the 
Bureau of Labor Statistics for calendar 
years 2013 through 2017.
502 
•HRES 1099 EH 
(II) The lowest average labor force 
participation rates based on data provided 
by the Bureau of Labor Statistics for cal-
endar years 2013 through 2017. 
(III) The highest age-adjusted rates 
of drug overdose deaths based on data 
from the Centers for Disease Control and 
Prevention. 
(ii) WEIGHTING.—The factors described 
in clause (i) shall be weighted as follows: 
(I) The rate described in clause (i)(I) 
shall be weighted at 15 percent. 
(II) The rate described in clause 
(i)(II) shall be weighted at 15 percent. 
(III) The rate described in clause 
(i)(III) shall be weighted at 70 percent. 
(3) DISTRIBUTION.—Amounts appropriated or oth-
erwise made available under this section shall be distrib-
uted according to the funding formula established by the 
Secretary under paragraph (1) not later than 30 days 
after the establishment of such formula. 
(c) USE OF FUNDS.— 
(1) IN GENERAL.—Any State that receives amounts 
pursuant to this section shall expend at least 30 percent
503 
•HRES 1099 EH 
of such funds within one year of the date funds become 
available to the grantee for obligation. 
(2) PRIORITY.—Any State that receives amounts 
pursuant to this section shall distribute such amounts 
giving priority to entities with the greatest need and 
ability to deliver effective assistance in a timely manner. 
(3) ADMINISTRATIVE COSTS.—Any State that re-
ceives amounts pursuant to this section may use up to 
5 percent of any grant for administrative costs. 
(d) RULES OF CONSTRUCTION.— 
(1) IN GENERAL.—Except as otherwise provided by 
this section, amounts appropriated, or amounts other-
wise made available to States under this section shall be 
treated as though such funds were community develop-
ment block grant funds under title I of the Housing and 
Community Development Act of 1974 (42 U.S.C. 5301 
et seq.). 
(2) NO MATCH.—No matching funds shall be re-
quired in order for a State to receive any amounts under 
this section. 
(e) AUTHORITY TO WAIVE OR SPECIFY ALTERNATIVE 
REQUIREMENTS.— 
(1) IN GENERAL.—In administering any amounts 
appropriated or otherwise made available under this sec-
tion, the Secretary may waive or specify alternative re-
504 
•HRES 1099 EH 
quirements to any provision under title I of the Housing 
and Community Development Act of 1974 (42 U.S.C. 
5301 et seq.) except for requirements related to fair 
housing, nondiscrimination, labor standards, the environ-
ment, and requirements that activities benefit persons of 
low- and moderate-income, upon a finding that such a 
waiver is necessary to expedite or facilitate the use of 
such funds. 
(2) NOTICE OF INTENT.—The Secretary shall pro-
vide written notice of its intent to exercise the authority 
to specify alternative requirements under paragraph (1) 
to the Committee on Banking, Housing, and Urban Af-
fairs of the Senate and the Committee on Financial 
Services of the House of Representatives not later than 
15 business days before such exercise of authority oc-
curs. 
(3) NOTICE TO THE PUBLIC.—The Secretary shall 
provide written notice of its intent to exercise the au-
thority to specify alternative requirements under para-
graph (1) to the public via notice, on the internet 
website of the Department of Housing and Urban Devel-
opment, and by other appropriate means, not later than 
15 business days before such exercise of authority oc-
curs.
505 
•HRES 1099 EH 
(f) TECHNICAL ASSISTANCE.—For the 2-year period fol-
lowing the date of enactment of this Act, the Secretary may 
use not more than 2 percent of the funds made available 
under this section for technical assistance to grantees. 
(g) STATE.—For purposes of this section the term 
‘‘State’’ includes any State as defined in section 102 of the 
Housing and Community Development Act of 1974 (42 
U.S.C. 5302) and the District of Columbia. 
Subtitle G—Human Services 
SEC. 
8081. 
SUPPORTING 
FAMILY-FOCUSED 
RESIDENTIAL 
TREATMENT. 
(a) DEFINITIONS.—In this section: 
(1) FAMILY-FOCUSED
RESIDENTIAL
TREATMENT 
PROGRAM.—The term ‘‘family-focused residential treat-
ment program’’ means a trauma-informed residential 
program primarily for substance use disorder treatment 
for pregnant and postpartum women and parents and 
guardians that allows children to reside with such 
women or their parents or guardians during treatment 
to the extent appropriate and applicable. 
(2) MEDICAID PROGRAM.—The term ‘‘Medicaid pro-
gram’’ means the program established under title XIX 
of the Social Security Act (42 U.S.C. 1396 et seq.). 
(3) SECRETARY.—The term ‘‘Secretary’’ means the 
Secretary of Health and Human Services.
506 
•HRES 1099 EH 
(4) TITLE IV–E PROGRAM.—The term ‘‘title IV–E 
program’’ means the program for foster care, prevention, 
and permanency established under part E of title IV of 
the Social Security Act (42 U.S.C. 670 et seq.). 
(b) GUIDANCE
ON
FAMILY-FOCUSED
RESIDENTIAL 
TREATMENT PROGRAMS.— 
(1) IN GENERAL.—Not later than 180 days after 
the date of enactment of this Act, the Secretary, in con-
sultation with divisions of the Department of Health and 
Human Services administering substance use disorder or 
child welfare programs, shall develop and issue guidance 
to States identifying opportunities to support family-fo-
cused residential treatment programs for the provision of 
substance use disorder treatment. Before issuing such 
guidance, the Secretary shall solicit input from rep-
resentatives of States, health care providers with exper-
tise in addiction medicine, obstetrics and gynecology, 
neonatology, child trauma, and child development, health 
plans, recipients of family-focused treatment services, 
and other relevant stakeholders. 
(2) ADDITIONAL
REQUIREMENTS.—The guidance 
required under paragraph (1) shall include descriptions 
of the following: 
(A) Existing opportunities and flexibilities 
under the Medicaid program, including under waiv-
507 
•HRES 1099 EH 
ers authorized under section 1115 or 1915 of the 
Social Security Act (42 U.S.C. 1315, 1396n), for 
States to receive Federal Medicaid funding for the 
provision of substance use disorder treatment for 
pregnant and postpartum women and parents and 
guardians and, to the extent applicable, their chil-
dren, in family-focused residential treatment pro-
grams. 
(B) How States can employ and coordinate 
funding provided under the Medicaid program, the 
title IV-E program, and other programs adminis-
tered by the Secretary to support the provision of 
treatment and services provided by a family-focused 
residential treatment facility such as substance use 
disorder treatment and services, including medica-
tion-assisted treatment, family, group, and indi-
vidual counseling, case management, parenting edu-
cation and skills development, the provision, assess-
ment, or coordination of care and services for chil-
dren, including necessary assessments and appro-
priate interventions, non-emergency transportation 
for necessary care provided at or away from a pro-
gram site, transitional services and supports for 
families leaving treatment, and other services.
508 
•HRES 1099 EH 
(C) How States can employ and coordinate 
funding provided under the Medicaid program and 
the title IV–E program (including as amended by 
the Family First Prevention Services Act enacted 
under title VII of division E of Public Law 115– 
123, and particularly with respect to the authority 
under subsections (a)(2)(C) and (j) of section 472 
and section 474(a)(1) of the Social Security Act (42 
U.S.C. 672, 674(a)(1)) (as amended by section 
50712 of Public Law 115–123) to provide foster 
care maintenance payments for a child placed with 
a parent who is receiving treatment in a licensed 
residential family-based treatment facility for a sub-
stance use disorder) to support placing children 
with their parents in family-focused residential 
treatment programs. 
SEC. 8082. IMPROVING RECOVERY AND REUNIFYING FAMILIES. 
(a) FAMILY RECOVERY AND REUNIFICATION PROGRAM 
REPLICATION PROJECT.—Section 435 of the Social Security 
Act (42 U.S.C. 629e) is amended by adding at the end the 
following: 
‘‘(e) FAMILY RECOVERY AND REUNIFICATION PROGRAM 
REPLICATION PROJECT.— 
‘‘(1) PURPOSE.—The purpose of this subsection is 
to provide resources to the Secretary to support the con-
509 
•HRES 1099 EH 
duct and evaluation of a family recovery and reunifica-
tion program replication project (referred to in this sub-
section as the ‘project’) and to determine the extent to 
which such programs may be appropriate for use at dif-
ferent intervention points (such as when a child is at 
risk of entering foster care or when a child is living with 
a guardian while a parent is in treatment). The family 
recovery and reunification program conducted under the 
project shall use a recovery coach model that is designed 
to help reunify families and protect children by working 
with parents or guardians with a substance use disorder 
who have temporarily lost custody of their children. 
‘‘(2) PROGRAM COMPONENTS.—The family recovery 
and reunification program conducted under the project 
shall adhere closely to the elements and protocol deter-
mined to be most effective in other recovery coaching 
programs that have been rigorously evaluated and shown 
to increase family reunification and protect children and, 
consistent with such elements and protocol, shall provide 
such items and services as— 
‘‘(A) assessments to evaluate the needs of the 
parent or guardian; 
‘‘(B) assistance in receiving the appropriate 
benefits to aid the parent or guardian in recovery;
510 
•HRES 1099 EH 
‘‘(C) services to assist the parent or guardian 
in prioritizing issues identified in assessments, es-
tablishing goals for resolving such issues that are 
consistent with the goals of the treatment provider, 
child welfare agency, courts, and other agencies in-
volved with the parent or guardian or their children, 
and making a coordinated plan for achieving such 
goals; 
‘‘(D) home visiting services coordinated with 
the child welfare agency and treatment provider in-
volved with the parent or guardian or their children; 
‘‘(E) case management services to remove bar-
riers for the parent or guardian to participate and 
continue in treatment, as well as to re-engage a 
parent or guardian who is not participating or pro-
gressing in treatment; 
‘‘(F) access to services needed to monitor the 
parent’s or guardian’s compliance with program re-
quirements; 
‘‘(G) frequent reporting between the treatment 
provider, child welfare agency, courts, and other 
agencies involved with the parent or guardian or 
their children to ensure appropriate information on 
the parent’s or guardian’s status is available to in-
form decision-making; and
511 
•HRES 1099 EH 
‘‘(H) assessments and recommendations pro-
vided by a recovery coach to the child welfare case-
worker responsible for documenting the parent’s or 
guardian’s progress in treatment and recovery as 
well as the status of other areas identified in the 
treatment plan for the parent or guardian, includ-
ing a recommendation regarding the expected safety 
of the child if the child is returned to the custody 
of the parent or guardian that can be used by the 
caseworker and a court to make permanency deci-
sions regarding the child. 
‘‘(3) RESPONSIBILITIES OF THE SECRETARY.— 
‘‘(A) IN
GENERAL.—The Secretary shall, 
through a grant or contract with 1 or more entities, 
conduct and evaluate the family recovery and reuni-
fication program under the project. 
‘‘(B) REQUIREMENTS.—In identifying 1 or 
more entities to conduct the evaluation of the family 
recovery and reunification program, the Secretary 
shall— 
‘‘(i) determine that the area or areas in 
which the program will be conducted have suf-
ficient substance use disorder treatment pro-
viders and other resources (other than those 
provided with funds made available to carry
512 
•HRES 1099 EH 
out the project) to successfully conduct the 
program; 
‘‘(ii) determine that the area or areas in 
which the program will be conducted have 
enough potential program participants, and 
will serve a sufficient number of parents or 
guardians and their children, so as to allow for 
the formation of a control group, evaluation re-
sults to be adequately powered, and prelimi-
nary results of the evaluation to be available 
within 4 years of the program’s implementa-
tion; 
‘‘(iii) provide the entity or entities with 
technical assistance for the program design, in-
cluding by working with 1 or more entities that 
are or have been involved in recovery coaching 
programs that have been rigorously evaluated 
and shown to increase family reunification and 
protect children so as to make sure the pro-
gram conducted under the project adheres 
closely to the elements and protocol determined 
to be most effective in such other recovery 
coaching programs; 
‘‘(iv) assist the entity or entities in secur-
ing adequate coaching, treatment, child wel-
513 
•HRES 1099 EH 
fare, court, and other resources needed to suc-
cessfully conduct the family recovery and re-
unification program under the project; and 
‘‘(v) ensure the entity or entities will be 
able to monitor the impacts of the program in 
the area or areas in which it is conducted for 
at least 5 years after parents or guardians and 
their children are randomly assigned to partici-
pate in the program or to be part of the pro-
gram’s control group. 
‘‘(4) EVALUATION REQUIREMENTS.— 
‘‘(A) IN
GENERAL.—The Secretary, in con-
sultation with the entity or entities conducting the 
family recovery and reunification program under 
the project, shall conduct an evaluation to deter-
mine whether the program has been implemented 
effectively and resulted in improvements for chil-
dren and families. The evaluation shall have 3 com-
ponents: a pilot phase, an impact study, and an im-
plementation study. 
‘‘(B) PILOT PHASE.—The pilot phase compo-
nent of the evaluation shall consist of the Secretary 
providing technical assistance to the entity or enti-
ties conducting the family recovery and reunifica-
tion program under the project to ensure—
514 
•HRES 1099 EH 
‘‘(i) the program’s implementation adheres 
closely to the elements and protocol determined 
to be most effective in other recovery coaching 
programs that have been rigorously evaluated 
and shown to increase family reunification and 
protect children; and 
‘‘(ii) random assignment of parents or 
guardians and their children to be participants 
in the program or to be part of the program’s 
control group is being carried out. 
‘‘(C) IMPACT STUDY.—The impact study com-
ponent of the evaluation shall determine the im-
pacts of the family recovery and reunification pro-
gram conducted under the project on the parents 
and guardians and their children participating in 
the program. The impact study component shall— 
‘‘(i) be conducted using an experimental 
design that uses a random assignment research 
methodology; 
‘‘(ii) consistent with previous studies of 
other recovery coaching programs that have 
been rigorously evaluated and shown to in-
crease family reunification and protect chil-
dren, measure outcomes for parents and
515 
•HRES 1099 EH 
guardians and their children over multiple time 
periods, including for a period of 5 years; and 
‘‘(iii) include measurements of family sta-
bility and parent, guardian, and child safety 
for program participants and the program con-
trol group that are consistent with measure-
ments of such factors for participants and con-
trol groups from previous studies of other re-
covery coaching programs so as to allow results 
of the impact study to be compared with the 
results of such prior studies, including with re-
spect to comparisons between program partici-
pants and the program control group regard-
ing— 
‘‘(I) safe family reunification; 
‘‘(II) time to reunification; 
‘‘(III) permanency (such as through 
measures of reunification, adoption, or 
placement with guardians); 
‘‘(IV) safety (such as through meas-
ures of subsequent maltreatment); 
‘‘(V) parental or guardian treatment 
persistence and engagement; 
‘‘(VI) parental or guardian substance 
use;
516 
•HRES 1099 EH 
‘‘(VII) juvenile delinquency; 
‘‘(VIII) cost; and 
‘‘(IX) other measurements agreed 
upon by the Secretary and the entity or 
entities operating the family recovery and 
reunification program under the project. 
‘‘(D) IMPLEMENTATION
STUDY.—The imple-
mentation study component of the evaluation shall 
be conducted concurrently with the conduct of the 
impact study component and shall include, in addi-
tion to such other information as the Secretary may 
determine, descriptions and analyses of— 
‘‘(i) the adherence of the family recovery 
and reunification program conducted under the 
project to other recovery coaching programs 
that have been rigorously evaluated and shown 
to increase family reunification and protect 
children; and 
‘‘(ii) the difference in services received or 
proposed to be received by the program partici-
pants and the program control group. 
‘‘(E) REPORT.—The Secretary shall publish on 
an internet website maintained by the Secretary the 
following information:
517 
•HRES 1099 EH 
‘‘(i) A report on the pilot phase compo-
nent of the evaluation. 
‘‘(ii) A report on the impact study compo-
nent of the evaluation. 
‘‘(iii) A report on the implementation 
study component of the evaluation. 
‘‘(iv) A report that includes— 
‘‘(I) analyses of the extent to which 
the program has resulted in increased re-
unifications, increased permanency, case 
closures, net savings to the State or 
States involved (taking into account both 
costs borne by States and the Federal 
government), or other outcomes, or if the 
program did not produce such outcomes, 
an analysis of why the replication of the 
program did not yield such results; 
‘‘(II) if, based on such analyses, the 
Secretary determines the program should 
be replicated, a replication plan; and 
‘‘(III) such recommendations for leg-
islation and administrative action as the 
Secretary determines appropriate. 
‘‘(5) APPROPRIATION.—In addition to any amounts 
otherwise made available to carry out this subpart, out
518 
•HRES 1099 EH 
of any money in the Treasury of the United States not 
otherwise 
appropriated, 
there 
are 
appropriated 
$15,000,000 for fiscal year 2019 to carry out the 
project, which shall remain available through fiscal year 
2026.’’. 
(b) CLARIFICATION OF PAYER OF LAST RESORT APPLI-
CATION
TO CHILD WELFARE PREVENTION
AND FAMILY 
SERVICES.—Section 471(e)(10) of the Social Security Act 
(42 U.S.C. 671(e)(10)), as added by section 50711(a)(2) of 
division E of Public Law 115–123, is amended— 
(1) in subparagraph (A), by inserting ‘‘, nor shall 
the provision of such services or programs be construed 
to permit the State to reduce medical or other assistance 
available to a recipient of such services or programs’’ 
after ‘‘under this Act’’; and 
(2) by adding at the end the following: 
‘‘(C) PAYER
OF
LAST
RESORT.—In carrying 
out its responsibilities to ensure access to services 
or programs under this subsection, the State agency 
shall not be considered to be a legally liable third 
party for purposes of satisfying a financial commit-
ment for the cost of providing such services or pro-
grams with respect to any individual for whom such 
cost would have been paid for from another public 
or private source but for the enactment of this sub-
519 
•HRES 1099 EH 
section (except that whenever considered necessary 
to prevent a delay in the receipt of appropriate 
early intervention services by a child or family in a 
timely fashion, funds provided under section 
474(a)(6) may be used to pay the provider of serv-
ices or programs pending reimbursement from the 
public or private source that has ultimate responsi-
bility for the payment).’’. 
(c) EFFECTIVE DATE.—The amendments made by sub-
section (b) shall take effect as if included in section 50711 
of division E of Public Law 115–123. 
SEC. 8083. BUILDING CAPACITY FOR FAMILY-FOCUSED RESI-
DENTIAL TREATMENT. 
(a) DEFINITIONS.—In this section: 
(1) ELIGIBLE ENTITY.—The term ‘‘eligible entity’’ 
means a State, county, local, or tribal health or child 
welfare agency, a private nonprofit organization, a re-
search organization, a treatment service provider, an in-
stitution of higher education (as defined under section 
101 of the Higher Education Act of 1965 (20 U.S.C. 
1001)), or another entity specified by the Secretary. 
(2) FAMILY-FOCUSED
RESIDENTIAL
TREATMENT 
PROGRAM.—The term ‘‘family-focused residential treat-
ment program’’ means a trauma-informed residential 
program primarily for substance use disorder treatment
520 
•HRES 1099 EH 
for pregnant and postpartum women and parents and 
guardians that allows children to reside with such 
women or their parents or guardians during treatment 
to the extent appropriate and applicable. 
(3) SECRETARY.—The term ‘‘Secretary’’ means the 
Secretary of Health and Human Services. 
(b) SUPPORT FOR THE DEVELOPMENT OF EVIDENCE- 
BASED FAMILY-FOCUSED RESIDENTIAL TREATMENT PRO-
GRAMS.— 
(1) AUTHORITY
TO
AWARD
GRANTS.—The Sec-
retary shall award grants to eligible entities for purposes 
of developing, enhancing, or evaluating family-focused 
residential treatment programs to increase the avail-
ability of such programs that meet the requirements for 
promising, supported, or well-supported practices speci-
fied in section 471(e)(4)(C) of the Social Security Act 
(42 U.S.C. 671(e)(4)(C))) (as added by the Family First 
Prevention Services Act enacted under title VII of divi-
sion E of Public Law 115–123). 
(2) EVALUATION
REQUIREMENT.—The Secretary 
shall require any evaluation of a family-focused residen-
tial treatment program by an eligible entity that uses 
funds awarded under this section for all or part of the 
costs of the evaluation be designed to assist in the deter-
mination of whether the program may qualify as a prom-
521 
•HRES 1099 EH 
ising, supported, or well-supported practice in accord-
ance with the requirements of such section 471(e)(4)(C). 
(c) AUTHORIZATION OF APPROPRIATIONS.—There is au-
thorized to be appropriated to the Secretary to carry out this 
section, $20,000,000 for fiscal year 2019, which shall remain 
available through fiscal year 2023. 
Subtitle H—Reauthorizing and Ex-
tending Grants for Recovery From 
Opioid Use Programs 
SEC. 8091. SHORT TITLE. 
This subtitle may be cited as the ‘‘Reauthorizing and 
Extending Grants for Recovery from Opioid Use Programs 
Act of 2018’’ or the ‘‘REGROUP Act of 2018’’. 
SEC. 
8092. 
REAUTHORIZATION 
OF 
THE 
COMPREHENSIVE 
OPIOID ABUSE GRANT PROGRAM. 
Section 1001(a)(27) of the Omnibus Crime Control and 
Safe Streets Act of 1968 (34 U.S.C. 10261(a)(27)) is amend-
ed by striking ‘‘through 2021’’ and inserting ‘‘and 2018, and 
$330,000,000 for each of fiscal years 2019 through 2023’’. 
Subtitle I—Fighting Opioid Abuse in 
Transportation 
SEC. 8101. SHORT TITLE. 
This subtitle may be cited as the ‘‘Fighting Opioid 
Abuse in Transportation Act’’.
522 
•HRES 1099 EH 
SEC. 8102. ALCOHOL AND CONTROLLED SUBSTANCE TESTING 
OF MECHANICAL EMPLOYEES. 
(a) IN GENERAL.—Not later than 2 years after the date 
of enactment of this Act, the Secretary of Transportation 
shall publish a rule in the Federal Register revising the regu-
lations promulgated under section 20140 of title 49, United 
States Code, to cover all employees of railroad carriers who 
perform mechanical activities. 
(b) DEFINITION OF MECHANICAL ACTIVITIES.—For the 
purposes of the rule under subsection (a), the Secretary shall 
define the term ‘‘mechanical activities’’ by regulation. 
SEC. 8103. DEPARTMENT OF TRANSPORTATION PUBLIC DRUG 
AND ALCOHOL TESTING DATABASE. 
(a) IN GENERAL.—Subject to subsection (c), the Sec-
retary of Transportation shall— 
(1) not later than March 31, 2019, establish and 
make publicly available on its website a database of the 
drug and alcohol testing data reported by employers for 
each mode of transportation; and 
(2) update the database annually. 
(b) CONTENTS.—The database under subsection (a) 
shall include, for each mode of transportation— 
(1) the total number of drug and alcohol tests by 
type of substance tested; 
(2) the drug and alcohol test results by type of sub-
stance tested;
523 
•HRES 1099 EH 
(3) the reason for the drug or alcohol test, such as 
pre-employment, random, post-accident, reasonable sus-
picion or cause, return-to-duty, or follow-up, by type of 
substance tested; and 
(4) the number of individuals who refused testing. 
(c) COMMERCIALLY SENSITIVE DATA.—The Department 
of Transportation shall not release any commercially sensitive 
data or personally identifiable data furnished by an employer 
under this section unless the data is aggregated or otherwise 
in a form that does not identify the employer providing the 
data. 
(d) SAVINGS CLAUSE.—Nothing in this section may be 
construed as limiting or otherwise affecting the requirements 
of the Secretary of Transportation to adhere to requirements 
applicable to confidential business information and sensitive 
security information, consistent with applicable law. 
SEC. 8104. GAO REPORT ON DEPARTMENT OF TRANSPOR-
TATION’S COLLECTION AND USE OF DRUG AND AL-
COHOL TESTING DATA. 
(a) IN GENERAL.—Not later than 2 years after the date 
the Department of Transportation public drug and alcohol 
testing database is established under section 8103, the Comp-
troller General of the United States shall—
524 
•HRES 1099 EH 
(1) review the Department of Transportation Drug 
and Alcohol Testing Management Information System; 
and 
(2) submit to the Committee on Commerce, Science, 
and Transportation of the Senate and the Committee on 
Transportation and Infrastructure of the House of Rep-
resentatives a report on the review, including rec-
ommendations under subsection (c). 
(b) CONTENTS.—The report under subsection (a) shall 
include— 
(1) a description of the process the Department of 
Transportation uses to collect and record drug and alco-
hol testing data submitted by employers for each mode 
of transportation; 
(2) an assessment of whether and, if so, how the 
Department of Transportation uses the data described in 
paragraph (1) in carrying out its responsibilities; and 
(3) an assessment of the Department of Transpor-
tation public drug and alcohol testing database under 
section 8103. 
(c) RECOMMENDATIONS.—The report under subsection 
(a) may include recommendations regarding— 
(1) how the Department of Transportation can best 
use the data described in subsection (b)(1);
525 
•HRES 1099 EH 
(2) any improvements that could be made to the 
process described in subsection (b)(1); 
(3) whether and, if so, how the Department of 
Transportation public drug and alcohol testing database 
under section 8103 could be made more effective; and 
(4) such other recommendations as the Comptroller 
General considers appropriate. 
SEC. 8105. TRANSPORTATION WORKPLACE DRUG AND ALCO-
HOL TESTING PROGRAM; ADDITION OF FENTANYL 
AND OTHER SUBSTANCES. 
(a) MANDATORY GUIDELINES
FOR FEDERAL WORK-
PLACE DRUG TESTING PROGRAMS.— 
(1) IN GENERAL.—Not later than 180 days after 
the date of enactment of this Act, the Secretary of 
Health and Human Services shall— 
(A) determine whether a revision of the Man-
datory Guidelines for Federal Workplace Drug 
Testing Programs to expand the opiate category on 
the list of authorized substance testing to include 
fentanyl is justified, based on the reliability and 
cost-effectiveness of available testing; and 
(B) consider whether to include with the deter-
mination under subparagraph (A) a separate deter-
mination on whether a revision of the Mandatory 
Guidelines for Federal Workplace Drug Testing
526 
•HRES 1099 EH 
Programs to expand the list of substances author-
ized for testing to include any other drugs or other 
substances listed in schedule I and II of section 202 
of the Controlled Substances Act (21 U.S.C. 812) 
is justified based on the criteria described in sub-
paragraph (A). 
(2) REVISION OF GUIDELINES.—If an expansion of 
the substance list is determined to be justified under 
paragraph (1), the Secretary of Health and Human 
Services shall— 
(A) notify the Committee on Commerce, 
Science, and Transportation of the Senate and the 
Committee on Transportation and Infrastructure of 
the House of Representatives of the determination; 
and 
(B) publish in the Federal Register, not later 
than 18 months after the date of the determination 
under that paragraph, a final notice of the revision 
of the Mandatory Guidelines for Federal Workplace 
Drug Testing Programs to expand the list of sub-
stances authorized to be tested to include the sub-
stance or substances determined to be justified for 
inclusion. 
(3) REPORT.—If an expansion of the substance list 
is determined not to be justified under paragraph (1),
527 
•HRES 1099 EH 
the Secretary of Health and Human Services shall sub-
mit to the Committee on Commerce, Science, and Trans-
portation of the Senate and the Committee on Transpor-
tation and Infrastructure of the House of Representa-
tives a report explaining, in detail, the reasons the ex-
pansion of the list of authorized substances is not justi-
fied. 
(b) DEPARTMENT OF TRANSPORTATION DRUG-TESTING 
PANEL.—If an expansion is determined to be justified under 
subsection (a)(1), the Secretary of Transportation shall pub-
lish in the Federal Register, not later than 18 months after 
the date the final notice is published under subsection (a)(2), 
a final rule revising part 40 of title 49, Code of Federal Reg-
ulations, to include such substances in the Department of 
Transportation’s drug-testing panel, consistent with the Man-
datory Guidelines for Federal Workplace Drug Testing Pro-
grams as revised by the Secretary of Health and Human 
Services under subsection (a). 
(c) SAVINGS PROVISION.—Nothing in this section may 
be construed as— 
(1) delaying the publication of the notices described 
in sections 8106 and 8107 of this Act until the Sec-
retary of Health and Human Services makes a deter-
mination or publishes a notice under this section; or
528 
•HRES 1099 EH 
(2) limiting or otherwise affecting any authority of 
the Secretary of Health and Human Services or the Sec-
retary of Transportation to expand the list of authorized 
substance testing to include an additional substance. 
SEC. 8106. STATUS REPORTS ON HAIR TESTING GUIDELINES. 
(a) IN GENERAL.—Not later than 60 days after the date 
of enactment of this Act, and annually thereafter until the 
date that the Secretary of Health and Human Services pub-
lishes in the Federal Register a final notice of scientific and 
technical guidelines for hair testing in accordance with sec-
tion 5402(b) of the Fixing America’s Surface Transportation 
Act (Public Law 114-94; 129 Stat. 1312), the Secretary of 
Health and Human Services shall submit to the Committee 
on Commerce, Science, and Transportation of the Senate and 
the Committee on Transportation and Infrastructure of the 
House of Representatives a report on— 
(1) the status of the hair testing guidelines; 
(2) an explanation for why the hair testing guide-
lines have not been issued; and 
(3) an estimated date of completion of the hair test-
ing guidelines. 
(b) REQUIREMENT.—To the extent practicable and con-
sistent with the objective of the hair testing described in sub-
section (a) to detect illegal or unauthorized use of substances 
by the individual being tested, the final notice of scientific
529 
•HRES 1099 EH 
and technical guidelines under that subsection, as determined 
by the Secretary of Health and Human Services, shall elimi-
nate the risk of positive test results, of the individual being 
tested, caused solely by the drug use of others and not caused 
by the drug use of the individual being tested. 
SEC. 8107. MANDATORY GUIDELINES FOR FEDERAL WORK-
PLACE DRUG TESTING PROGRAMS USING ORAL 
FLUID. 
(a) DEADLINE.—Not later than December 31, 2018, the 
Secretary of Health and Human Services shall publish in the 
Federal Register a final notice of the Mandatory Guidelines 
for Federal Workplace Drug Testing Programs using Oral 
Fluid, based on the notice of proposed mandatory guidelines 
published in the Federal Register on May 15, 2015 (94 FR 
28054). 
(b) REQUIREMENT.—To the extent practicable and con-
sistent with the objective of the testing described in sub-
section (a) to detect illegal or unauthorized use of substances 
by the individual being tested, the final notice of scientific 
and technical guidelines under that subsection, as determined 
by the Secretary of Health and Human Services, shall elimi-
nate the risk of positive test results, of the individual being 
tested, caused solely by the drug use of others and not caused 
by the drug use of the individual being tested.
530 
•HRES 1099 EH 
(c) RULE OF CONSTRUCTION.—Nothing in this section 
may be construed as requiring the Secretary of Health and 
Human Services to reissue a notice of proposed mandatory 
guidelines to carry out subsection (a). 
SEC. 8108. ELECTRONIC RECORDKEEPING. 
(a) DEADLINE.—Not later than 1 year after the date of 
enactment of this Act, the Secretary of Health and Human 
Services shall— 
(1) ensure that each certified laboratory that re-
quests approval for the use of completely paperless elec-
tronic Federal Drug Testing Custody and Control Forms 
from the National Laboratory Certification Program’s 
Electronic Custody and Control Form systems receives 
approval for those completely paperless electronic forms 
instead of forms that include any combination of elec-
tronic traditional handwritten signatures executed on 
paper forms; and 
(2) establish a deadline for a certified laboratory to 
request approval under paragraph (1). 
(b) SAVINGS CLAUSE.—Nothing in this section may be 
construed as limiting or otherwise affecting any authority of 
the Secretary of Health and Human Services to grant ap-
proval to a certified laboratory for use of completely paperless 
electronic Federal Drug Testing Custody and Control Forms,
531 
•HRES 1099 EH 
including to grant approval outside of the process under sub-
section (a). 
(c) ELECTRONIC
SIGNATURES.—Not later than 18 
months after the date of the deadline under subsection (a)(2), 
the Secretary of Transportation shall issue a final rule revis-
ing part 40 of title 49, Code of Federal Regulations, to au-
thorize, to the extent practicable, the use of electronic signa-
tures or digital signatures executed to electronic forms in-
stead of traditional handwritten signatures executed on paper 
forms. 
SEC. 8109. STATUS REPORTS ON COMMERCIAL DRIVER’S LI-
CENSE DRUG AND ALCOHOL CLEARINGHOUSE. 
(a) IN GENERAL.—Not later than 60 days after the date 
of enactment of this Act, and annually thereafter until the 
compliance date, the Administrator of the Federal Motor Car-
rier Safety Administration shall submit to the Committee on 
Commerce, Science, and Transportation of the Senate and 
the Committee on Transportation and Infrastructure of the 
House of Representatives a status report on implementation 
of the final rule for the Commercial Driver’s License Drug 
and Alcohol Clearinghouse (81 FR 87686), including— 
(1) an updated schedule, including benchmarks, for 
implementing the final rule as soon as practicable, but 
not later than the compliance date; and
532 
•HRES 1099 EH 
(2) a description of each action the Federal Motor 
Carrier Safety Administration is taking to implement the 
final rule before the compliance date. 
(b) DEFINITION OF COMPLIANCE DATE.—In this sec-
tion, the term ‘‘compliance date’’ means the earlier of— 
(1) January 6, 2020; or 
(2) the date that the national clearinghouse re-
quired under section 31306a of title 49, United States 
Code, is operational. 
Subtitle J—Eliminating Kickbacks in 
Recovery 
SEC. 8121. SHORT TITLE. 
This subtitle may be cited as the ‘‘Eliminating Kick-
backs in Recovery Act of 2018’’. 
SEC. 8122. CRIMINAL PENALTIES. 
(a) IN GENERAL.—Chapter 11 of title 18, United States 
Code, is amended by inserting after section 219 the following: 
‘‘§ 220. Illegal remunerations for referrals to recovery 
homes, clinical treatment facilities, and lab-
oratories 
‘‘(a) OFFENSE.—Except as provided in subsection (b), 
whoever, with respect to services covered by a health care 
benefit program, in or affecting interstate or foreign com-
merce, knowingly and willfully—
533 
•HRES 1099 EH 
‘‘(1) solicits or receives any remuneration (including 
any kickback, bribe, or rebate) directly or indirectly, 
overtly or covertly, in cash or in kind, in return for re-
ferring a patient or patronage to a recovery home, clin-
ical treatment facility, or laboratory; or 
‘‘(2) pays or offers any remuneration (including any 
kickback, bribe, or rebate) directly or indirectly, overtly 
or covertly, in cash or in kind— 
‘‘(A) to induce a referral of an individual to a 
recovery home, clinical treatment facility, or labora-
tory; or 
‘‘(B) in exchange for an individual using the 
services of that recovery home, clinical treatment 
facility, or laboratory, 
shall be fined not more than $200,000, imprisoned not more 
than 10 years, or both, for each occurrence. 
‘‘(b) APPLICABILITY.—Subsection (a) shall not apply 
to— 
‘‘(1) a discount or other reduction in price obtained 
by a provider of services or other entity under a health 
care benefit program if the reduction in price is properly 
disclosed and appropriately reflected in the costs claimed 
or charges made by the provider or entity; 
‘‘(2) a payment made by an employer to an em-
ployee or independent contractor (who has a bona fide
534 
•HRES 1099 EH 
employment or contractual relationship with such em-
ployer) for employment, if the employee’s payment is not 
determined by or does not vary by— 
‘‘(A) the number of individuals referred to a 
particular recovery home, clinical treatment facility, 
or laboratory; 
‘‘(B) the number of tests or procedures per-
formed; or 
‘‘(C) the amount billed to or received from, in 
part or in whole, the health care benefit program 
from the individuals referred to a particular recov-
ery home, clinical treatment facility, or laboratory; 
‘‘(3) a discount in the price of an applicable drug 
of a manufacturer that is furnished to an applicable ben-
eficiary under the Medicare coverage gap discount pro-
gram under section 1860D–14A(g) of the Social Secu-
rity Act (42 U.S.C. 1395w–114a(g)); 
‘‘(4) a payment made by a principal to an agent as 
compensation for the services of the agent under a per-
sonal services and management contract that meets the 
requirements of section 1001.952(d) of title 42, Code of 
Federal Regulations, as in effect on the date of enact-
ment of this section; 
‘‘(5) a waiver or discount (as defined in section 
1001.952(h)(5) of title 42, Code of Federal Regulations,
535 
•HRES 1099 EH 
or any successor regulation) of any coinsurance or co-
payment by a health care benefit program if— 
‘‘(A) the waiver or discount is not routinely 
provided; and 
‘‘(B) the waiver or discount is provided in good 
faith; 
‘‘(6) 
a 
remuneration 
described 
in 
section 
1128B(b)(3)(I) of the Social Security Act (42 U.S.C. 
1320a–7b(b)(3)(I)); 
‘‘(7) a remuneration made pursuant to an alter-
native 
payment 
model 
(as 
defined 
in 
section 
1833(z)(3)(C) of the Social Security Act) or pursuant to 
a payment arrangement used by a State, health insur-
ance issuer, or group health plan if the Secretary of 
Health and Human Services has determined that such 
arrangement is necessary for care coordination or value- 
based care; or 
‘‘(8) any other payment, remuneration, discount, or 
reduction as determined by the Attorney General, in con-
sultation with the Secretary of Health and Human Serv-
ices, by regulation. 
‘‘(c) REGULATIONS.—The Attorney General, in consulta-
tion with the Secretary of Health and Human Services, may 
promulgate regulations to clarify the exceptions described in 
subsection (b).
536 
•HRES 1099 EH 
‘‘(d) PREEMPTION.— 
‘‘(1) FEDERAL LAW.—This section shall not apply 
to conduct that is prohibited under section 1128B of the 
Social Security Act (42 U.S.C. 1320a–7b). 
‘‘(2) STATE LAW.—Nothing in this section shall be 
construed to occupy the field in which any provisions of 
this section operate to the exclusion of State laws on the 
same subject matter. 
‘‘(e) DEFINITIONS.—In this section— 
‘‘(1) the terms ‘applicable beneficiary’ and ‘applica-
ble drug’ have the meanings given those terms in section 
1860D–14A(g) of the Social Security Act (42 U.S.C. 
1395w–114a(g)); 
‘‘(2) the term ‘clinical treatment facility’ means a 
medical setting , other than a hospital, that provides de-
toxification, risk reduction, outpatient treatment and 
care, residential treatment, or rehabilitation for sub-
stance use, pursuant to licensure or certification under 
State law; 
‘‘(3) the term ‘health care benefit program’ has the 
meaning given the term in section 24(b); 
‘‘(4) the term ‘laboratory’ has the meaning given 
the term in section 353 of the Public Health Service Act 
(42 U.S.C. 263a); and
537 
•HRES 1099 EH 
‘‘(5) the term ‘recovery home’ means a shared living 
environment that is, or purports to be, free from alcohol 
and illicit drug use and centered on peer support and 
connection to services that promote sustained recovery 
from substance use disorders.’’. 
(b) CLERICAL AMENDMENT.—The table of sections for 
chapter 11 of title 18, United States Code, is amended by in-
serting after the item related to section 219 the following: 
‘‘220. Illegal remunerations for referrals to recovery homes, clinical treatment 
facilities, and laboratories.’’. 
Subtitle K—Substance Abuse 
Prevention 
SEC. 8201. SHORT TITLE. 
This subtitle may be cited as the ‘‘Substance Abuse Pre-
vention Act of 2018’’. 
SEC. 8202. REAUTHORIZATION OF THE OFFICE OF NATIONAL 
DRUG CONTROL POLICY. 
(a) OFFICE OF NATIONAL DRUG CONTROL POLICY RE-
AUTHORIZATION ACT OF 1998.— 
(1) IN
GENERAL.—The Office of National Drug 
Control Policy Reauthorization Act of 1998 (21 U.S.C. 
1701 et seq.), as in effect on September 29, 2003, and 
as amended by the laws described in paragraph (2), is 
revived and restored. 
(2) LAWS DESCRIBED.—The laws described in this 
paragraph are:
538 
•HRES 1099 EH 
(A) The Office of National Drug Control Pol-
icy Reauthorization Act of 2006 (Public Law 109– 
469; 120 Stat. 3502). 
(B) The Presidential Appointment Efficiency 
and Streamlining Act of 2011 (Public Law 112– 
166; 126 Stat. 1283). 
(b) REAUTHORIZATION.— 
(1) IN GENERAL.—Section 714 of the Office of Na-
tional Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1711) is amended by striking ‘‘such sums as 
may be necessary for each of fiscal years 2006 through 
2010’’ and inserting ‘‘$18,400,000 for each of fiscal 
years 2018 through 2023’’. 
(2) REPEAL OF TERMINATION.—The Office of Na-
tional Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1701 et seq.) is amended by striking section 
715 (21 U.S.C. 1712). 
SEC. 8203. REAUTHORIZATION OF THE DRUG-FREE COMMU-
NITIES PROGRAM. 
(a) REVIVAL
OF NATIONAL NARCOTICS LEADERSHIP 
ACT OF 1988.— 
(1) IN GENERAL.—Chapter 2 of the National Nar-
cotics Leadership Act of 1988 (21 U.S.C. 1521 et seq.), 
except for subchapter II (21 U.S.C. 1541 et seq.), as in
539 
•HRES 1099 EH 
effect on September 29, 1997, and as amended by the 
laws described in paragraph (2), is revived and restored. 
(2) LAWS DESCRIBED.—The laws described in this 
paragraph are: 
(A) Public Law 107–82 (115 Stat. 814). 
(B) The Office of National Drug Control Pol-
icy Reauthorization Act of 2006 (Public Law 109– 
469: 120 Stat. 3502), as amended by paragraph 
(4). 
(3) AMENDMENT
TO
TERMINATION
PROVISION.— 
Section 1009 of the National Narcotics Leadership Act 
of 1988 (21 U.S.C. 1056) is amended by inserting ‘‘and 
sections 1021 through 1035’’ after ‘‘section 1007’’. 
(4) TECHNICAL CORRECTION.— 
(A) IN GENERAL.—Title VIII of the Office of 
National Drug Control Policy Reauthorization Act 
of 2006 (Public Law 109–469; 120 Stat. 3535) is 
amended by striking ‘‘Drug-Free Communities Act 
of 1997’’ each place it appears and inserting ‘‘Na-
tional Narcotics Leadership Act of 1988’’. 
(B) 
EFFECTIVE
DATE.—The 
amendments 
made by subparagraph (A) shall take effect as 
though enacted as part of the Office of National 
Drug Control Policy Reauthorization Act of 2006 
(Public Law 109–469; 120 Stat. 3502).
540 
•HRES 1099 EH 
(b) AMENDMENT
TO NATIONAL NARCOTICS LEADER-
SHIP ACT OF 1988.—Chapter 2 of subtitle A of title I of the 
National Narcotics Leadership Act of 1988 (21 U.S.C. 1521 
et seq.) is amended— 
(1) in section 1022 (21 U.S.C. 1522), by striking 
‘‘substance abuse’’ each place it appears and inserting 
‘‘substance use and misuse’’; 
(2) in section 1023 (21 U.S.C. 1523), by striking 
paragraph (9) and inserting the following: 
‘‘(9) SUBSTANCE
USE
AND
MISUSE.—The term 
‘substance use and misuse’ means— 
‘‘(A) the illegal use or misuse of drugs, includ-
ing substances for which a listing is effect under 
any of schedules I through V under section 202 of 
the Controlled Substances Act (21 U.S.C. 812); 
‘‘(B) the misuse of inhalants or over-the- 
counter drugs; or 
‘‘(C) the use of alcohol, tobacco, or other re-
lated product as such use is prohibited by State or 
local law.’’; 
(3) in section 1024 (21 U.S.C. 1524), by striking 
subsections (a) and (b) and inserting the following: 
‘‘(a) IN GENERAL.—There is authorized to be appro-
priated to the Office of National Drug Control Policy to carry
541 
•HRES 1099 EH 
out this chapter $99,000,000 for each of fiscal years 2018 
through 2023. 
‘‘(b) ADMINISTRATIVE COSTS.—Not more than 8 per-
cent of the funds appropriated to carry out this chapter may 
be used by the Office of National Drug Control Policy to pay 
administrative costs associated with the responsibilities of the 
Office under this chapter.’’; 
(4) in subchapter I (21 U.S.C. 1531 et seq.)— 
(A) by striking ‘‘substance abuse’’ each place it 
appears and inserting ‘‘substance use and misuse’’; 
and 
(B) in section 1032(b)(1)(A) (21 U.S.C. 
1532(b)(1)(A)), by striking clause (iii) and insert-
ing the following: 
‘‘(iii) 
RENEWAL
GRANTS.—Subject 
to 
clause (iv), the Administrator may award a re-
newal grant to a grant recipient under this 
subparagraph for each fiscal year of the 4-fis-
cal-year period following the first fiscal year 
for which the initial additional grant is award-
ed in an amount not to exceed the following: 
‘‘(I) For the first and second fiscal 
years of the 4-fiscal-year period, the 
amount of the non-Federal funds, includ-
ing in-kind contributions, raised by the co-
542 
•HRES 1099 EH 
alition for the applicable fiscal year is not 
less than 125 percent of the amount 
awarded. 
‘‘(II) For the third and fourth fiscal 
tears of the 4-fiscal-year period, the 
amount of the non-Federal funds, includ-
ing in-kind contributions, raised by the co-
alition for the applicable fiscal year is not 
less than 150 percent of the amount 
awarded.’’; and 
(5) by striking subchapter II (21 U.S.C. 1541 et 
seq.). 
SEC. 8204. REAUTHORIZATION OF THE NATIONAL COMMUNITY 
ANTI-DRUG COALITION INSTITUTE. 
Section 4 of Public Law 107–82 (21 U.S.C. 1521 note) 
is amended to read as follows: 
‘‘SEC. 4. AUTHORIZATION FOR NATIONAL COMMUNITY ANTI-
DRUG COALITION INSTITUTE. 
‘‘(a) IN GENERAL.—The Director shall, using amounts 
authorized to be appropriated by subsection (d), make a com-
petitive grant to provide for the continuation of the National 
Community Anti-drug Coalition Institute. 
‘‘(b) ELIGIBLE ORGANIZATIONS.—An organization eligi-
ble for the grant under subsection (a) is any national non-
profit organization that represents, provides technical assist-
543 
•HRES 1099 EH 
ance and training to, and has special expertise and broad, na-
tional-level experience in community antidrug coalitions under 
this subchapter. 
‘‘(c) USE OF GRANT AMOUNT.—The organization that 
receives the grant under subsection (a) shall continue a Na-
tional Community Anti-Drug Coalition Institute to— 
‘‘(1) provide education, training, and technical as-
sistance for coalition leaders and community teams, with 
emphasis on the development of coalitions serving eco-
nomically disadvantaged areas; 
‘‘(2) develop and disseminate evaluation tools, 
mechanisms, and measures to better assess and docu-
ment coalition performance measures and outcomes; and 
‘‘(3) bridge the gap between research and practice 
by translating knowledge from research into practical in-
formation. 
‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—The Direc-
tor shall, using amounts authorized to be appropriated by 
section 1032 of the National Narcotics Leadership Act of 
1988 (15 U.S.C. 1532), make a grant of $2 million under 
subsection (a), for each of the fiscal years 2018 through 
2023.’’.
544 
•HRES 1099 EH 
SEC. 8205. REAUTHORIZATION OF THE HIGH-INTENSITY DRUG 
TRAFFICKING AREA PROGRAM. 
Section 707 of the Office of National Drug Control Pol-
icy Reauthorization Act of 1998 (21 U.S.C. 1706) is amend-
ed— 
(1) in subsection (f), by striking ‘‘no Federal’’ and 
all that follows through ‘‘programs.’’ and inserting the 
following: ‘‘not more than a total of 5 percent of Federal 
funds appropriated for the Program are expended for 
substance use disorder treatment programs and drug 
prevention programs.’’; 
(2) in subsection (p)— 
(A) in paragraph (4), by striking ‘‘and’’ at the 
end; 
(B) in paragraph (5), by striking the period at 
the end and inserting ‘‘; and’’; and 
(C) by adding at the end the following: 
‘‘(6) $280,000,000 for each of fiscal years 2018 
through 2023.’’; and 
(3) in subsection (q)— 
(A) by striking paragraph (2) and inserting the 
following: 
‘‘(2) REQUIRED
USES.—The funds used under 
paragraph (1) shall be used to ensure the safety of 
neighborhoods and the protection of communities, in-
cluding the prevention of the intimidation of witnesses of
545 
•HRES 1099 EH 
illegal drug distribution and related activities and the es-
tablishment of, or support for, programs that provide 
protection or assistance to witnesses in court pro-
ceedings.’’; and 
(B) by adding at the end the following: 
‘‘(3) BEST PRACTICE MODELS.—The Director shall 
work with HIDTAs to develop and maintain best prac-
tice models to assist State, local, and Tribal govern-
ments in addressing witness safety, relocation, financial 
and housing assistance, or any other services related to 
witness protection or assistance in cases of illegal drug 
distribution and related activities. The Director shall en-
sure dissemination of the best practice models to each 
HIDTA.’’. 
SEC. 8206. REAUTHORIZATION OF DRUG COURT PROGRAM. 
Section 1001(a)(25)(A) of title I of the Omnibus Crime 
Control and Safe Streets Act of 1968 (34 U.S.C. 
10261(a)(25)(A)) is amended by striking ‘‘Except as pro-
vided’’ and all that follows and inserting the following: ‘‘Ex-
cept as provided in subparagraph (C), there is authorized to 
be appropriated to carry out part EE $75,000,000 for each 
of fiscal years 2018 through 2023.’’.
546 
•HRES 1099 EH 
SEC. 8207. DRUG COURT TRAINING AND TECHNICAL ASSIST-
ANCE. 
Section 705 of the Office of National Drug Control Pol-
icy Reauthorization Act of 1998 (21 U.S.C. 1704) is amend-
ed by adding at the end the following: 
‘‘(e) DRUG COURT TRAINING AND TECHNICAL ASSIST-
ANCE PROGRAM.— 
‘‘(1) GRANTS
AUTHORIZED.—The Director may 
make a grant to a nonprofit organization for the purpose 
of providing training and technical assistance to drug 
courts. 
‘‘(2) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this sub-
section $2,000,000 for each of fiscal years 2018 through 
2023.’’. 
SEC. 8208. DRUG OVERDOSE RESPONSE STRATEGY. 
Section 707 of the Office of National Drug Control Pol-
icy Reauthorization Act of 1998 (21 U.S.C. 1706) is amend-
ed by adding at the end the following: 
‘‘(r) DRUG OVERDOSE RESPONSE STRATEGY IMPLE-
MENTATION.—The Director may use funds appropriated to 
carry out this section to implement a drug overdose response 
strategy in high intensity drug trafficking areas on a nation-
wide basis by— 
‘‘(1) coordinating multi-disciplinary efforts to pre-
vent, reduce, and respond to drug overdoses, including
547 
•HRES 1099 EH 
the uniform reporting of fatal and non-fatal overdoses to 
public health and safety officials; 
‘‘(2) increasing data sharing among public safety 
and public health officials concerning drug-related abuse 
trends, including new psychoactive substances, and re-
lated crime; and 
‘‘(3) enabling collaborative deployment of preven-
tion, intervention, and enforcement resources to address 
substance use addiction and narcotics trafficking.’’. 
SEC. 8209. PROTECTING LAW ENFORCEMENT OFFICERS FROM 
ACCIDENTAL EXPOSURE. 
Section 707 of the Office of National Drug Control Pol-
icy Reauthorization Act of 1998 (21 U.S.C. 1706), as amend-
ed by section 8208, is amended by adding at the end the fol-
lowing: 
‘‘(s) SUPPLEMENTAL GRANTS.—The Director is author-
ized to use not more than $10,000,000 of the amounts other-
wise appropriated to carry out this section to provide supple-
mental competitive grants to high intensity drug trafficking 
areas that have experienced high seizures of fentanyl and new 
psychoactive substances for the purposes of— 
‘‘(1) purchasing portable equipment to test for 
fentanyl and other substances;
548 
•HRES 1099 EH 
‘‘(2) training law enforcement officers and other 
first responders on best practices for handling fentanyl 
and other substances; and 
‘‘(3) purchasing protective equipment, including 
overdose reversal drugs.’’. 
SEC. 8210. COPS ANTI-METH PROGRAM. 
Section 1701 of title I of the Omnibus Crime Control 
and Safe Streets Act of 1968 (34 U.S.C. 10381) is amend-
ed— 
(1) by redesignating subsection (k) as subsection 
(l); and 
(2) by inserting after subsection (j) the following: 
‘‘(k) COPS ANTI-METH PROGRAM.—The Attorney Gen-
eral shall use amounts otherwise appropriated to carry out 
this section for a fiscal year (beginning with fiscal year 2019) 
to make competitive grants, in amounts of not less than 
$1,000,000 for such fiscal year, to State law enforcement 
agencies with high seizures of precursor chemicals, finished 
methamphetamine, laboratories, and laboratory dump sei-
zures for the purpose of locating or investigating illicit activi-
ties, such as precursor diversion, laboratories, or meth-
amphetamine traffickers.’’.
549 
•HRES 1099 EH 
SEC. 8211. COPS ANTI-HEROIN TASK FORCE PROGRAM. 
Section 1701 of title I of the Omnibus Crime Control 
and Safe Streets Act of 1968 (34 U.S.C. 10381) is amend-
ed— 
(1) by redesignating subsection (l), as so redesig-
nated by section 8210, as subsection (m); and 
(2) by inserting after subsection (k), as added by 
section 8210, the following: 
‘‘(l) COPS ANTI-HEROIN TASK FORCE PROGRAM.—The 
Attorney General shall use amounts otherwise appropriated 
to carry out this section, or other amounts as appropriated, 
for a fiscal year (beginning with fiscal year 2019) to make 
competitive grants to State law enforcement agencies in 
States with high per capita rates of primary treatment ad-
missions, for the purpose of locating or investigating illicit ac-
tivities, through Statewide collaboration, relating to the dis-
tribution of heroin, fentanyl, or carfentanil or relating to the 
unlawful distribution of prescription opioids.’’. 
SEC. 8212. COMPREHENSIVE ADDICTION AND RECOVERY ACT 
EDUCATION AND AWARENESS. 
Title VII of the Comprehensive Addiction and Recovery 
Act of 2016 (Public Law 114–198; 130 Stat. 735) is amend-
ed by adding at the end the following: 
‘‘SEC. 709. SERVICES FOR FAMILIES AND PATIENTS IN CRISIS. 
‘‘(a) IN
GENERAL.—The Secretary of Health and 
Human Services may make grants to entities that focus on
550 
•HRES 1099 EH 
addiction and substance use disorders and specialize in family 
and patient services, advocacy for patients and families, and 
educational information. 
‘‘(b) ALLOWABLE USES.—A grant awarded under this 
section may be used for nonprofit national, State, or local or-
ganizations that engage in the following activities: 
‘‘(1) Expansion of resource center services with pro-
fessional, clinical staff that provide, for families and in-
dividuals impacted by a substance use disorder, support, 
access to treatment resources, brief assessments, medica-
tion and overdose prevention education, compassionate 
listening services, recovery support or peer specialists, 
bereavement and grief support, and case management. 
‘‘(2) Continued development of health information 
technology systems that leverage new and upcoming 
technology and techniques for prevention, intervention, 
and filling resource gaps in communities that are under-
served. 
‘‘(3) Enhancement and operation of treatment and 
recovery resources, easy-to-read scientific and evidence- 
based education on addiction and substance use dis-
orders, and other informational tools for families and in-
dividuals impacted by a substance use disorder and com-
munity stakeholders, such as law enforcement agencies.
551 
•HRES 1099 EH 
‘‘(4) Provision of training and technical assistance 
to State and local governments, law enforcement agen-
cies, health care systems, research institutions, and other 
stakeholders. 
‘‘(5) Expanding upon and implementing educational 
information using evidence-based information on sub-
stance use disorders. 
‘‘(6) Expansion of training of community stake-
holders, law enforcement officers, and families across a 
broad-range of addiction, health, and related topics on 
substance use disorders, local issues and community-spe-
cific issues related to the drug epidemic. 
‘‘(7) Program evaluation.’’. 
SEC. 8213. REIMBURSEMENT OF SUBSTANCE USE DISORDER 
TREATMENT PROFESSIONALS. 
Not later than January 1, 2020, the Comptroller Gen-
eral of the United States shall submit to Congress a report 
examining how substance use disorder services are reim-
bursed. 
SEC. 8214. SOBRIETY TREATMENT AND RECOVERY TEAMS 
(START). 
Title V of the Public Health Service Act (42 U.S.C. 
290dd et seq.) is amended by adding at the end the following:
552 
•HRES 1099 EH 
‘‘SEC. 550. SOBRIETY TREATMENT AND RECOVERY TEAMS. 
‘‘(a) IN GENERAL.—The Secretary may make grants to 
States, units of local government, or tribal governments to es-
tablish or expand Sobriety Treatment And Recovery Team 
(referred to in this section as ‘START’) or other similar pro-
grams to determine the effectiveness of pairing social workers 
or mentors with families that are struggling with a substance 
use disorder and child abuse or neglect in order to help pro-
vide peer support, intensive treatment, and child welfare serv-
ices to such families. 
‘‘(b) ALLOWABLE USES.—A grant awarded under this 
section may be used for one or more of the following activi-
ties: 
‘‘(1) Training eligible staff, including social work-
ers, social services coordinators, child welfare specialists, 
substance use disorder treatment professionals, and 
mentors. 
‘‘(2) Expanding access to substance use disorder 
treatment services and drug testing. 
‘‘(3) Enhancing data sharing with law enforcement 
agencies, child welfare agencies, substance use disorder 
treatment providers, judges, and court personnel. 
‘‘(4) Program evaluation and technical assistance. 
‘‘(c) PROGRAM REQUIREMENTS.—A State, unit of local 
government, or tribal government receiving a grant under 
this section shall—
553 
•HRES 1099 EH 
‘‘(1) serve only families for which— 
‘‘(A) there is an open record with the child wel-
fare agency; and 
‘‘(B) substance use disorder was a reason for 
the record or finding described in paragraph (1); 
and 
‘‘(2) coordinate any grants awarded under this sec-
tion with any grant awarded under section 437(f) of the 
Social Security Act focused on improving outcomes for 
children affected by substance abuse. 
‘‘(d) TECHNICAL ASSISTANCE.—The Secretary may re-
serve not more than 5 percent of funds provided under this 
section to provide technical assistance on the establishment or 
expansion of programs funded under this section from the 
National Center on Substance Abuse and Child Welfare.’’. 
SEC. 8215. PROVIDER EDUCATION. 
Not later than 60 days after the date of enactment of 
this Act, the Attorney General, in consultation with the Sec-
retary of Health and Human Services, shall complete the 
plan related to medical registration coordination required by 
Senate Report 114–239, which accompanied the Veterans 
Care Financial Protection Act of 2017 (Public Law 115–131; 
132 Stat. 334).
554 
•HRES 1099 EH 
SEC. 8216. DEFINITIONS. 
Section 702 of the Office of National Drug Control Pol-
icy Reauthorization Act of 1998 (21 U.S.C. 1701) is amend-
ed— 
(1) by striking paragraphs (5), (12), and (13); 
(2) by redesignating paragraph (11) as paragraph 
(17); 
(3) by redesignating paragraphs (9) and (10) as 
paragraphs (14) and (15), respectively; 
(4) by redesignating paragraphs (6), (7), and (8) as 
paragraphs (10), (11), and (12), respectively; 
(5) by redesignating paragraphs (1), (2), (3), and 
(4) as paragraphs (3), (4), (5), and (6), respectively; 
(6) by inserting before paragraph (3), as so redesig-
nated, the following: 
‘‘(1) AGENCY.—The term ‘agency’ has the meaning 
given the term ‘executive agency’ in section 102 of title 
31, United States Code. 
‘‘(2) 
APPROPRIATE
CONGRESSIONAL
COMMIT-
TEES.— 
‘‘(A) IN
GENERAL.—The term ‘appropriate 
congressional committees’ means— 
‘‘(i) the Committee on the Judiciary, the 
Committee on Appropriations, and the Com-
mittee on Health, Education, Labor, and Pen-
sions of the Senate; and
555 
•HRES 1099 EH 
‘‘(ii) the Committee on Oversight and 
Government Reform, the Committee on the Ju-
diciary, the Committee on Energy and Com-
merce, and the Committee on Appropriations 
of the House of Representatives. 
‘‘(B) SUBMISSION
TO
CONGRESS.—Any sub-
mission to Congress shall mean submission to the 
appropriate congressional committees.’’; 
(7) by amending paragraph (3), as so redesignated, 
to read as follows: 
‘‘(3) DEMAND REDUCTION.—The term ‘demand re-
duction’ means any activity conducted by a National 
Drug Control Program Agency, other than an enforce-
ment activity, that is intended to reduce or prevent the 
use of drugs or support, expand, or provide treatment 
and recovery efforts, including— 
‘‘(A) education about the dangers of illicit drug 
use; 
‘‘(B) services, programs, or strategies to pre-
vent substance use disorder, including evidence- 
based education campaigns, community-based pre-
vention programs, collection and disposal of unused 
prescription drugs, and services to at-risk popu-
lations to prevent or delay initial use of an illicit 
drug;
556 
•HRES 1099 EH 
‘‘(C) substance use disorder treatment; 
‘‘(D) support for long-term recovery from sub-
stance use disorders; 
‘‘(E) drug-free workplace programs; 
‘‘(F) drug testing, including the testing of em-
ployees; 
‘‘(G) interventions for illicit drug use and de-
pendence; 
‘‘(H) expanding availability of access to health 
care services for the treatment of substance use dis-
orders; 
‘‘(I) international drug control coordination 
and cooperation with respect to activities described 
in this paragraph; 
‘‘(J) pre- and post-arrest criminal justice inter-
ventions such as diversion programs, drug courts, 
and the provision of evidence-based treatment to in-
dividuals with substance use disorders who are ar-
rested or under some form of criminal justice super-
vision, including medication assisted treatment; 
‘‘(K) other coordinated and joint initiatives 
among Federal, State, local, and Tribal agencies to 
promote comprehensive drug control strategies de-
signed to reduce the demand for, and the avail-
ability of, illegal drugs;
557 
•HRES 1099 EH 
‘‘(L) international illicit drug use education, 
prevention, treatment, recovery, research, rehabilita-
tion activities, and interventions for illicit drug use 
and dependence; and 
‘‘(M) research related to illicit drug use and 
any of the activities described in this paragraph.’’; 
(8) by inserting after paragraph (6), as so redesig-
nated, the following: 
‘‘(7) EMERGING DRUG THREAT.—The term ‘emerg-
ing drug threat’ means the occurrence of a new and 
growing trend in the use of an illicit drug or class of 
drugs, including rapid expansion in the supply of or de-
mand for such drug. 
‘‘(8) ILLICIT DRUG USE; ILLICIT DRUGS; ILLEGAL 
DRUGS.—The terms ‘illicit drug use’, ‘illicit drugs’, and 
‘illegal drugs’ include the illegal or illicit use of prescrip-
tion drugs. 
‘‘(9) LAW ENFORCEMENT.—The term ‘law enforce-
ment’ or ‘drug law enforcement’ means all efforts by a 
Federal, State, local, or Tribal government agency to en-
force the drug laws of the United States or any State, 
including investigation, arrest, prosecution, and incarcer-
ation or other punishments or penalties.’’; 
(9) by amending paragraph (11), as so redesig-
nated, to read as follows:
558 
•HRES 1099 EH 
‘‘(11) NATIONAL DRUG CONTROL PROGRAM AGEN-
CY.—The term ‘National Drug Control Program Agency’ 
means any agency (or bureau, office, independent agen-
cy, board, division, commission, subdivision, unit, or 
other component thereof) that is responsible for imple-
menting any aspect of the National Drug Control Strat-
egy, including any agency that receives Federal funds to 
implement any aspect of the National Drug Control 
Strategy, but does not include any agency that receives 
funds for drug control activity solely under the National 
Intelligence Program or the Joint Military Intelligence 
Program.’’; 
(10) in paragraph (12), as so redesignated— 
(A) by inserting ‘‘or ‘Strategy’ ’’ before 
‘‘means’’; and 
(B) by inserting ‘‘, including any report, plan, 
or strategy required to be incorporated into or 
issued concurrently with such strategy’’ before the 
period at the end; 
(11) by inserting after paragraph (12), as so redes-
ignated, the following: 
‘‘(13) NONPROFIT ORGANIZATION.—The term ‘non-
profit organization’ means an organization that is de-
scribed in section 501(c)(3) of the Internal Revenue
559 
•HRES 1099 EH 
Code of 1986 and exempt from tax under section 501(a) 
of such Code.’’; 
(12) in paragraph (14), as so redesignated, by 
striking ‘‘Unless the context clearly indicates otherwise, 
the’’ and inserting ‘‘The’’; 
(13) by inserting after paragraph (15), as so redes-
ignated, the following: 
‘‘(16) SUBSTANCE USE DISORDER TREATMENT.— 
The term ‘substance use disorder treatment’ means an 
evidence-based, professionally directed, deliberate, and 
planned regimen including evaluation, observation, med-
ical monitoring, and rehabilitative services and interven-
tions such as pharmacotherapy, behavioral therapy, and 
individual and group counseling, on an inpatient or out-
patient basis, to help patients with substance use dis-
order reach recovery.’’; and 
(14) in paragraph (17), as so redesignated— 
(A) by redesignating subparagraphs (B), (C), 
(D), and (E), as subparagraphs (C), (D), (E), and 
(F), respectively; 
(B) by inserting after subparagraph (A) the 
following: 
‘‘(B) domestic law enforcement;’’; 
(C) in subparagraph (E), as so redesignated, 
by striking ‘‘and’’ at the end;
560 
•HRES 1099 EH 
(D) in subparagraph (F), as so redesignated, 
by striking the period at the end and inserting a 
semicolon; and 
(E) by adding at the end the following: 
‘‘(G) activities to prevent the diversion of 
drugs for their illicit use; and 
‘‘(H) research related to any of the activities 
described in this paragraph.’’. 
SEC. 8217. AMENDMENTS TO ADMINISTRATION OF THE OFFICE. 
(a) RESPONSIBILITIES OF OFFICE.—Section 703(a) of 
the Office of National Drug Control Policy Reauthorization 
Act of 1998 (21 U.S.C. 1702(a)) is amended— 
(1) by striking paragraph (1) and inserting the fol-
lowing: 
‘‘(1) lead the national drug control effort, including 
coordinating with the National Drug Control Program 
Agencies;’’; 
(2) in paragraph (2), by inserting before the semi-
colon the following: ‘‘, including the National Drug Con-
trol Strategy’’; 
(3) in paragraph (3), by striking ‘‘and’’ at the end; 
and 
(4) by striking paragraph (4) and all that follows 
through ‘‘the National Academy of Sciences.’’ and in-
serting the following:
561 
•HRES 1099 EH 
‘‘(4) evaluate the effectiveness of national drug con-
trol policy efforts, including the National Drug Control 
Program Agencies’ program, by developing and applying 
specific goals and performance measurements and moni-
toring the agencies’ program-level spending; 
‘‘(5) identify and respond to emerging drug threats 
related to illicit drug use; 
‘‘(6) administer the Drug-Free Communities Pro-
gram, the High-Intensity Drug Trafficking Areas Pro-
gram, and other grant programs directly authorized to 
be administered by the Office in furtherance of the Na-
tional Drug Control Strategy; and 
‘‘(7) facilitate broad-scale information sharing and 
data standardization among Federal, State, and local en-
tities to support the national drug control efforts.’’. 
(b) ETHICS GUIDELINES.—Section 703(d) of the Office 
of National Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1702(d)) is amended by adding at the end the fol-
lowing: 
‘‘(4) ETHICS GUIDELINES.—The Director shall es-
tablish written guidelines setting forth the criteria to be 
used in determining whether a gift or donation should be 
declined under this subsection because the acceptance of 
the gift or donation would—
562 
•HRES 1099 EH 
‘‘(A) reflect unfavorably upon the ability of the 
Director or the Office, or any employee of the Of-
fice, to carry out responsibilities or official duties 
under this chapter in a fair and objective manner; 
or 
‘‘(B) compromise the integrity or the appear-
ance of integrity of programs or services provided 
under this chapter or of any official involved in 
those programs or services. 
‘‘(5) REGISTRY
OF
GIFTS.—The Director shall 
maintain a list of— 
‘‘(A) the source and amount of each gift or do-
nation accepted by the Office; and 
‘‘(B) the source and amount of each gift or do-
nation accepted by a contractor to be used in its 
performance of a contract for the Office. 
‘‘(6) REPORT TO CONGRESS.—The Director shall 
include in the annual assessment under section 706(g) a 
copy of the registry maintained under paragraph (5).’’. 
(c) APPOINTMENT OF DIRECTOR AND DEPUTY DIREC-
TOR.—Section 704(a) of the Office of National Drug Control 
Policy Reauthorization Act of 1998 (21 U.S.C. 1703(a)) is 
amended— 
(1) in paragraph (1), by striking subparagraphs 
(A), (B), and (C), and inserting the following:
563 
•HRES 1099 EH 
‘‘(A) DIRECTOR.— 
‘‘(i) IN GENERAL.—There shall be at the 
head of the Office a Director who shall hold 
the same rank and status as the head of an ex-
ecutive department listed in section 101 of title 
5, United States Code. 
‘‘(ii) APPOINTMENT.—The Director shall 
be appointed by the President, by and with the 
advice and consent of the Senate, and shall 
serve at the pleasure of the President. 
‘‘(B) DEPUTY
DIRECTOR.—There shall be a 
Deputy Director who shall report directly to the Di-
rector, and who shall be appointed by the President, 
and shall serve at the pleasure of the President. 
‘‘(C) COORDINATORS.—The following coordina-
tors shall be appointed by the Director: 
‘‘(i) Performance Budget Coordinator, as 
described in section 704(c)(4). 
‘‘(ii) Interdiction Coordinator, as de-
scribed in section 711. 
‘‘(iii) Emerging and Continuing Threats 
Coordinator, as described in section 709. 
‘‘(iv) State, Local, and Tribal Affairs Co-
ordinator, to carry out the activities described 
in section 704(j).
564 
•HRES 1099 EH 
‘‘(v) Demand Reduction Coordinator, as 
described in subparagraph (D). 
‘‘(D) DEMAND
REDUCTION
COORDINATOR.— 
The Director shall designate or appoint a United 
States Demand Reduction Coordinator to be re-
sponsible for the activities described in section 
702(3). The Director shall determine whether the 
coordinator position is a noncareer appointee in the 
Senior Executive Service or a career appointee in a 
position at level 15 of the General Schedule (or 
equivalent).’’; 
(2) in paragraph (5), by striking ‘‘such official’’ and 
inserting ‘‘such officer or employee’’; and 
(3) by adding at the end the following: 
‘‘(6) PROHIBITION
ON
THE
USE
OF
FUNDS
FOR 
BALLOT INITIATIVES.—No funds authorized under this 
title may be obligated for the purpose of expressly advo-
cating the passage or defeat of a State or local ballot ini-
tiative.’’. 
(d) CONSULTATION.—Section 704(b) of the Office of 
National Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1703(b)) is amended— 
(1) in paragraph (19), by striking ‘‘; and’’ and in-
serting a semicolon;
565 
•HRES 1099 EH 
(2) in paragraph (20), by striking the period at the 
end and inserting ‘‘; and’’; and 
(3) by adding at the end the following: 
‘‘(21) in order to formulate the national drug con-
trol policies, goals, objectives, and priorities— 
‘‘(A) shall consult with and assist— 
‘‘(i) State and local governments; 
‘‘(ii) National Drug Control Program 
Agencies; 
‘‘(iii) each committee, working group, 
council, or other entity established under this 
chapter, as appropriate; 
‘‘(iv) the public; 
‘‘(v) appropriate congressional commit-
tees; and 
‘‘(vi) any other person in the discretion of 
the Director; and 
‘‘(B) may— 
‘‘(i) establish advisory councils; 
‘‘(ii) acquire data from agencies; and 
‘‘(iii) request data from any other enti-
ty.’’. 
(e) NATIONAL DRUG CONTROL PROGRAM BUDGET.— 
Section 704(c) of the Office of National Drug Control Policy
566 
•HRES 1099 EH 
Reauthorization Act of 1998 (21 U.S.C. 1703(c)) is amend-
ed— 
(1) in paragraph (2)— 
(A) in subparagraph (A), by striking ‘‘para-
graph (1)(C);’’ and inserting the following: ‘‘para-
graph (1)(C) and include— 
‘‘(i) the funding level for each National 
Drug Control Program agency; and 
‘‘(ii) alternative funding structures that 
could improve progress on achieving the goals 
fo the National Drug Control Strategy; and’’; 
(B) in subparagraph (B), strike ‘‘the Presi-
dent; and’’ and inserting ‘‘the President and Con-
gress.’’; and 
(C) by striking subparagraph (C); 
(2) in paragraph (3)(E), by striking clause (ii) and 
inserting the following: 
‘‘(ii) 
CERTIFICATION.—The 
Director 
shall— 
‘‘(I) review each budget submission 
submitted under subparagraph (A); 
‘‘(II) based on the review under 
clause (i), make a determination as to 
whether the budget submission of a Na-
tional Drug Control Program agency in-
567 
•HRES 1099 EH 
cludes the funding levels and initiatives 
described in subparagraph (B); and 
‘‘(III) submit to the appropriate con-
gressional committees— 
‘‘(aa) a written statement that 
either— 
‘‘(AA) certifies that the 
budget submission includes suffi-
cient funding; or 
‘‘(BB) decertifies the budg-
et submission as not including 
sufficient funding; 
‘‘(bb) a copy of the description 
made under subparagraph (B); and 
‘‘(cc) the budget recommenda-
tions made under subsection (b)(8).’’; 
and 
(3) by adding at the end the following: 
‘‘(5) PERFORMANCE-BUDGET COORDINATOR.— 
‘‘(A) DESIGNATION.—The Director shall des-
ignate or appoint a United States Performance- 
Budget Coordinator to— 
‘‘(i) ensure the Director has sufficient in-
formation necessary to analyze the perform-
ance of each National Drug Control Program
568 
•HRES 1099 EH 
Agency, the impact Federal funding has had 
on the goals in the Strategy, and the likely 
contributions to the goals of the Strategy 
based on funding levels of each National Drug 
Control Program Agency, to make an inde-
pendent assessment of the budget request of 
each agency under this subsection; 
‘‘(ii) advise the Director on agency budg-
ets, performance measures and targets, and 
additional data and research needed to make 
informed policy decisions under this section 
and section 706; and 
‘‘(iii) other duties as may be determined 
by the Director with respect to measuring or 
assessing performance or agency budgets. 
‘‘(B) DETERMINATION OF POSITION.—The Di-
rector shall determine whether the coordinator posi-
tion is a noncareer appointee in the Senior Execu-
tive Service or a career appointee in a position at 
level 15 of the General Schedule (or equivalent). 
‘‘(6) BUDGET ESTIMATE OR REQUEST SUBMISSION 
TO
CONGRESS.—Whenever the Director submits any 
budget estimate or request to the President or the Office 
of Management and Budget, the Director shall concur-
rently transmit to the appropriate congressional commit-
569 
•HRES 1099 EH 
tees a detailed statement of the budgetary needs of the 
Office to execute its mission based on the good-faith as-
sessment of the Director.’’. 
(f) POWERS
AND RESPONSIBILITIES
OF
THE DIREC-
TOR.—Section 704 of the Office of National Drug Control 
Policy Reauthorization Act of 1998 (21 U.S.C. 1703) is 
amended— 
(1) in subsection (d)(8)— 
(A) in subparagraph (D), by striking ‘‘and’’ at 
the end; 
(B) in subparagraph (E)— 
(i) in clause (i)— 
(I) by striking ‘‘Congress, including 
to the Committees on Appropriations of 
the Senate and the House of Representa-
tives, the authorizing committees for the 
Office,’’ and inserting ‘‘the appropriate 
congressional committees’’; and 
(II) by striking ‘‘or agencies’’; 
(ii) in clause (ii)— 
(I) by striking ‘‘Congress’’ and in-
serting ‘‘the appropriate congressional 
committees’’; and 
(II) by adding ‘‘and’’ at the end; and 
(iii) by adding at the end the following:
570 
•HRES 1099 EH 
‘‘(iii) funds may only be used for— 
‘‘(I) expansion of demand reduction 
activities; 
‘‘(II) interdiction of illicit drugs on 
the high seas, in United States territorial 
waters, and at United States ports of 
entry by officers and employees of Na-
tional Drug Control Program Agencies 
and domestic and foreign law enforcement 
officers; 
‘‘(III) accurate assessment and moni-
toring of international drug production 
and interdiction programs and policies; 
‘‘(IV) activities to facilitate and en-
hance the sharing of domestic and foreign 
intelligence information among National 
Drug Control Program Agencies related to 
the production and trafficking of drugs in 
the United States and foreign countries; 
and 
‘‘(V) research related to any of these 
activities.’’; 
(2) in subsection (e)(2)(A), by striking ‘‘Notwith-
standing any other provision of law’’ and inserting ‘‘Sub-
ject to the availability of appropriations’’; and
571 
•HRES 1099 EH 
(3) by adding at the end the following: 
‘‘(i) MODEL ACTS PROGRAM.— 
‘‘(1) IN GENERAL.—The Director shall provide for 
or shall enter into an agreement with a nonprofit organi-
zation to— 
‘‘(A) advise States on establishing laws and 
policies to address illicit drug use issues; and 
‘‘(B) revise such model State drug laws and 
draft supplementary model State laws to take into 
consideration changes in illicit drug use issues in 
the State involved. 
‘‘(2) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this sub-
section $1,250,000 for each of fiscal years 2018 through 
2023. 
‘‘(j) STATE, LOCAL, AND TRIBAL AFFAIRS COORDI-
NATOR.—The Director shall designate or appoint a United 
States State, Local, and Tribal Affairs Coordinator to per-
form the duties of the Office outlined in this section and 706 
and such other duties as may be determined by the Director 
with respect to coordination of drug control efforts between 
agencies and State, local, and Tribal governments. The Direc-
tor shall determine whether the coordinator position is a non-
career appointee in the Senior Executive Service or a career
572 
•HRES 1099 EH 
appointee in a position at level 15 of the General Schedule 
(or equivalent). 
‘‘(k) HARM REDUCTION PROGRAMS .—When developing 
the national drug control policy, any policy of the Director, 
including policies relating to syringe exchange programs for 
intravenous drug users, shall be based on the best available 
medical and scientific evidence regarding the effectiveness of 
such policy in promoting individual health and preventing the 
spread of infectious disease and the impact of such policy on 
drug addiction and use. In making any policy relating to 
harm reduction programs, the Director shall consult with the 
National Institutes of Health and the National Academy of 
Sciences.’’. 
(g) ACCOUNTING OF FUNDS EXPENDED.—Section 705 
of the Office of National Drug Control Policy Reauthoriza-
tion Act of 1998 (21 U.S.C. 1704(d)), as amended by section 
8207 is further amended— 
(1) by amending subsection (d) to read as follows: 
‘‘(d) ACCOUNTING OF FUNDS EXPENDED.— 
‘‘(1) IN GENERAL.—Not later than February 1 of 
each year, in accordance with guidance issued by the Di-
rector, the head of each National Drug Control Program 
Agency shall submit to the Director a detailed account-
ing of all funds expended by the agency for National 
Drug Control Program activities during the previous fis-
573 
•HRES 1099 EH 
cal year and shall ensure such detailed accounting is au-
thenticated for the previous fiscal year by the Inspector 
General for such agency prior to the submission to the 
Director as frequently as determined by the Inspector 
General but not less frequently that every 3 years. 
‘‘(2) SUBMISSION
TO
CONGRESS.—The Director 
shall submit to Congress not later than April 1 of each 
year the information submitted to the Director under 
paragraph (1).’’; and 
(2) by adding at the end the following: 
‘‘(f) TRACKING
SYSTEM
FOR
FEDERALLY
FUNDED 
GRANT PROGRAMS.— 
‘‘(1) ESTABLISHMENT.—The Director, or the head 
of an agency designated by the Director, in coordination 
with the Secretary of Health and Human Services, shall 
track federally-funded grant programs to— 
‘‘(A) ensure the public has electronic access to 
information identifying: 
‘‘(i) all drug control grants and pertinent 
identifying information for each grant; 
‘‘(ii) any available performance metrics, 
evaluations, or other information indicating the 
effectiveness of such programs; 
‘‘(B) facilitate efforts to identify duplication, 
overlap, or gaps in funding to provide increased ac-
574 
•HRES 1099 EH 
countability of Federally-funded grants for sub-
stance use disorder treatment, prevention, and en-
forcement; and 
‘‘(C) identify barriers in the grant application 
process impediments that applicants currently have 
in the grant application process with applicable 
agencies. 
‘‘(2) NATIONAL
DRUG
CONTROL
AGENCIES.—The 
head of each National Drug Control Program Agency 
shall provide to the Director a complete list of all drug 
control program grant programs and any other relevant 
information for inclusion in the system developed under 
paragraph (1) and annually update such list. 
‘‘(3) UPDATING EXISTING SYSTEMS.—The Director 
may meet the requirements of this subsection by uti-
lizing, updating, or improving existing Federal informa-
tion systems to ensure they meet the requirements of 
this subsection. 
‘‘(4) REPORT.—Not later than 3 years after the 
date of enactment of this subsection, the Comptroller 
General of the United States shall submit to Congress 
a report examining implementation of this subsection.’’. 
(h) TECHNICAL AND CONFORMING AMENDMENT.—Sec-
tion 1105 of the Office of National Drug Control Policy Re-
authorization Act of 2006 (21 U.S.C. 1701 note) is repealed.
575 
•HRES 1099 EH 
SEC. 8218. EMERGING THREATS COMMITTEE, PLAN, AND MEDIA 
CAMPAIGN. 
(a) IN GENERAL.—Section 709 of the Office of National 
Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 
1708) is amended to read as follows: 
‘‘SEC. 709. EMERGING THREATS COMMITTEE, PLAN, AND MEDIA 
CAMPAIGN. 
‘‘(a) EMERGING THREATS COORDINATOR.—The Director 
shall designate or appoint a United States Emerging and 
Continuing Threats Coordinator to perform the duties of that 
position described in this section and such other duties as 
may be determined by the Director. The Director shall deter-
mine whether the coordinator position is a noncareer ap-
pointee in the Senior Executive Service or a career appointee 
in a position at level 15 of the General Schedule (or equiva-
lent). 
‘‘(b) EMERGING THREATS COMMITTEE.— 
‘‘(1) IN GENERAL.—The Emerging Threats Com-
mittee shall— 
‘‘(A) monitor evolving and emerging drug 
threats in the United States; 
‘‘(B) identify and discuss evolving and emerg-
ing drug trends in the United States using the cri-
teria required to be established under paragraph 
(6);
576 
•HRES 1099 EH 
‘‘(C) assist in the formulation of and oversee 
implementation of any plan described in subsection 
(d); 
‘‘(D) provide such other advice to the Coordi-
nator and Director concerning strategy and policies 
for emerging drug threats and trends as the Com-
mittee determines to be appropriate; and 
‘‘(E) disseminate and facilitate the sharing 
with Federal, State, local, and Tribal officials and 
other entities as determined by the Director of per-
tinent information and data relating to— 
‘‘(i) recent trends in drug supply and de-
mand; 
‘‘(ii) fatal and nonfatal overdoses; 
‘‘(iii) demand for and availability of evi-
dence-based substance use disorder treatment, 
including the extent of the unmet treatment 
need, and treatment admission trends; 
‘‘(iv) recent trends in drug interdiction, 
supply, and demand from State, local, and 
Tribal law enforcement agencies; and 
‘‘(v) other subject matter as determined 
necessary by the Director.
577 
•HRES 1099 EH 
‘‘(2) CHAIRPERSON.—The Director shall designate 
one of the members of the Emerging Threats Committee 
to serve as Chairperson. 
‘‘(3) MEMBERS.—The Director shall appoint other 
members of the Committee, which shall include— 
‘‘(A) representatives from National Drug Con-
trol Program Agencies or other agencies; 
‘‘(B) representatives from State, local, and 
Tribal governments; and 
‘‘(C) representatives from other entities as des-
ignated by the Director. 
‘‘(4) MEETINGS.—The members of the Emerging 
Threats Committee shall meet, in person and not 
through any delegate or representative, not less fre-
quently than once per calendar year, before June 1. At 
the call of the Director or the Chairperson, the Emerg-
ing Threats Committee may hold additional meetings as 
the members may choose. 
‘‘(5) CONTRACT, AGREEMENT, AND OTHER AUTHOR-
ITY.—The Director may award contracts, enter into 
interagency agreements, manage individual projects, and 
conduct other activities in support of the identification 
of emerging drug threats and in support of the develop-
ment, implementation, and assessment of any Emerging 
Threat Response Plan.
578 
•HRES 1099 EH 
‘‘(6) CRITERIA
TO
IDENTIFY
EMERGING
DRUG 
THREATS.—Not later than 180 days after the date on 
which the Committee first meets, the Committee shall 
develop and recommend to the Director criteria to be 
used to identify an emerging drug threat or the termi-
nation of an emerging drug threat designation based on 
information gathered by the Committee, statistical data, 
and other evidence. 
‘‘(c) DESIGNATION.— 
‘‘(1) IN GENERAL.—The Director, in consultation 
with the Coordinator, the Committee, and the head of 
each National Drug Control Program Agency, may des-
ignate an emerging drug threat in the United States. 
‘‘(2) STANDARDS FOR DESIGNATION.—The Direc-
tor, in consultation with the Coordinator, shall promul-
gate and make publicly available standards by which a 
designation under paragraph (1) and the termination of 
such designation may be made. In developing such 
standards, the Director shall consider the recommenda-
tions of the committee and other criteria the Director 
considers to be appropriate. 
‘‘(3) PUBLIC STATEMENT REQUIRED.—The Direc-
tor shall publish a public written statement on the portal 
of the Office explaining the designation of an emerging 
drug threat or the termination of such designation and
579 
•HRES 1099 EH 
shall notify the appropriate congressional committees of 
the availability of such statement when a designation or 
termination of such designation has been made. 
‘‘(d) PLAN.— 
‘‘(1) PUBLIC
AVAILABILITY
OF
PLAN.—Not later 
than 90 days after making a designation under sub-
section (c), the Director shall publish and make publicly 
available an Emerging Threat Response Plan and notify 
the President and the appropriate congressional commit-
tees of such plan’s availability. 
‘‘(2) TIMING.—Concurrently with the annual sub-
missions under section 706(g), the Director shall update 
the plan and report on implementation of the plan, until 
the Director issues the public statement required under 
subsection (c)(3) to terminate the emerging drug threat 
designation. 
‘‘(3) CONTENTS
OF
AN
EMERGING
THREAT
RE-
SPONSE PLAN.—The Director shall include in the plan 
required under this subsection— 
‘‘(A) a comprehensive strategic assessment of 
the emerging drug threat, including the current 
availability of, demand for, and effectiveness of evi-
dence-based prevention, treatment, and enforcement 
programs and efforts to respond to the emerging 
drug threat;
580 
•HRES 1099 EH 
‘‘(B) comprehensive, research-based, short- and 
long-term, quantifiable goals for addressing the 
emerging drug threat, including for reducing the 
supply of the drug designated as the emerging drug 
threat and for expanding the availability and effec-
tiveness of evidence-based substance use disorder 
treatment and prevention programs to reduce the 
demand for the emerging drug threat; 
‘‘(C) performance measures pertaining to the 
plan’s goals, including quantifiable and measurable 
objectives and specific targets; 
‘‘(D) the level of funding needed to implement 
the plan, including whether funding is available to 
be reprogrammed or transferred to support imple-
mentation of the plan or whether additional appro-
priations are necessary to implement the plan; 
‘‘(E) an implementation strategy for the media 
campaign under subsection (f), including goals as 
described under subparagraph (B) of this para-
graph and performance measures, objectives, and 
targets, as described under subparagraph (C) of 
this paragraph; and 
‘‘(F) any other information necessary to inform 
the public of the status, progress, or response of an 
emerging drug threat.
581 
•HRES 1099 EH 
‘‘(4) IMPLEMENTATION.— 
‘‘(A) IN GENERAL.—Not later than 120 days 
after the date on which a designation is made under 
subsection (c), the Director, in consultation with the 
President, the appropriate congressional commit-
tees, and the head of each National Drug Control 
Program Agency, shall issue guidance on implemen-
tation of the plan described in this subsection to the 
National Drug Control Program Agencies and any 
other relevant agency determined to be necessary by 
the Director. 
‘‘(B) 
COORDINATOR’S
RESPONSIBILITIES.— 
The Coordinator shall— 
‘‘(i) direct the implementation of the plan 
among the agencies identified in the plan, 
State, local, and Tribal governments, and other 
relevant entities; 
‘‘(ii) facilitate information-sharing be-
tween agencies identified in the plan, State, 
local, and Tribal governments, and other rel-
evant entities; and 
‘‘(iii) monitor implementation of the plan 
by coordinating the development and imple-
mentation of collection and reporting systems 
to support performance measurement and ad-
582 
•HRES 1099 EH 
herence to the plan by agencies identified in 
plan, where appropriate. 
‘‘(C) REPORTING.—Not later than 180 days 
after the date on which a designation is made under 
subsection (c) and in accordance with subparagraph 
(A), the head of each agency identified in the plan 
shall submit to the Coordinator a report on imple-
mentation of the plan. 
‘‘(e) EVALUATION
OF MEDIA CAMPAIGN.—Upon des-
ignation of an emerging drug threat, the Director shall evalu-
ate whether a media campaign would be appropriate to ad-
dress that threat. 
‘‘(f) NATIONAL ANTI-DRUG MEDIA CAMPAIGN.— 
‘‘(1) IN GENERAL.—The Director shall, to the ex-
tent feasible and appropriate, conduct a national anti- 
drug media campaign (referred to in this subtitle as the 
‘national media campaign’) in accordance with this sub-
section for the purposes of— 
‘‘(A) preventing substance abuse among people 
in the United States; 
‘‘(B) educating the public about the dangers 
and negative consequences of substance use and 
abuse, including patient and family education about 
the characteristics and hazards of substance abuse 
and methods to safeguard against substance use, to
583 
•HRES 1099 EH 
include the safe disposal of prescription medica-
tions; 
‘‘(C) supporting evidence-based prevention pro-
grams targeting the attitudes, perception, and be-
liefs of persons concerning substance use and inten-
tions to initiate or continue such use; 
‘‘(D) encouraging individuals affected by sub-
stance use disorders to seek treatment and pro-
viding such individuals with information on— 
‘‘(i) how to recognize addiction issues; 
‘‘(ii) what forms of evidence-based treat-
ment options are available; and 
‘‘(iii) how to access such treatment; 
‘‘(E) combating the stigma of addiction and 
substance use disorders, including the stigma of 
treating such disorders with medication-assisted 
treatment therapies; and 
‘‘(F) informing the public about the dangers of 
any drug identified by the Director as an emerging 
drug threat as appropriate. 
‘‘(2) USE OF FUNDS.— 
‘‘(A) IN GENERAL.—Amounts made available 
to carry out this subsection for the national media 
campaign may only be used for the following:
584 
•HRES 1099 EH 
‘‘(i) The purchase of media time and 
space, including the strategic planning for, 
tracking, and accounting of, such purchases. 
‘‘(ii) Creative and talent costs, consistent 
with subparagraph (B)(i). 
‘‘(iii) Advertising production costs, which 
may include television, radio, internet, social 
media, 
and 
other 
commercial 
marketing 
venues. 
‘‘(iv) Testing and evaluation of adver-
tising. 
‘‘(v) Evaluation of the effectiveness of the 
national media campaign. 
‘‘(vi) Costs of contracts to carry out ac-
tivities authorized by this subsection. 
‘‘(vii) Partnerships with professional and 
civic groups, community-based organizations, 
including faith-based organizations, and gov-
ernment organizations related to the national 
media campaign. 
‘‘(viii) Entertainment industry outreach, 
interactive outreach, media projects and activi-
ties, public information, news media outreach, 
and corporate sponsorship and participation.
585 
•HRES 1099 EH 
‘‘(ix) Operational and management ex-
penses. 
‘‘(B) SPECIFIC REQUIREMENTS.— 
‘‘(i) 
CREATIVE
SERVICES.—In 
using 
amounts for creative and talent costs under 
subparagraph (A)(ii), the Director shall use 
creative services donated at no cost to the Gov-
ernment wherever feasible and may only pro-
cure creative services for advertising— 
‘‘(I) responding to high-priority or 
emergent campaign needs that cannot 
timely be obtained at no cost; or 
‘‘(II) intended to reach a minority, 
ethnic, or other special audience that can-
not reasonably be obtained at no cost. 
‘‘(ii) TESTING AND EVALUATION OF AD-
VERTISING.—In using amounts for testing and 
evaluation of advertising under subparagraph 
(A)(iv), the Director shall test all advertise-
ments prior to use in the national media cam-
paign to ensure that the advertisements are ef-
fective with the target audience and meet in-
dustry-accepted standards. The Director may 
waive this requirement for advertisements 
using no more than 10 percent of the purchase
586 
•HRES 1099 EH 
of advertising time purchased under this sub-
section in a fiscal year and no more than 10 
percent of the advertising space purchased 
under this subsection in a fiscal year, if the ad-
vertisements respond to emergent and time- 
sensitive campaign needs or the advertisements 
will not be widely utilized in the national media 
campaign. 
‘‘(iii) CONSULTATION.—For the planning 
of the campaign under paragraph (1), the Di-
rector may consult with— 
‘‘(I) the head of any appropriate Na-
tional Drug Control Program Agency; 
‘‘(II) experts on the designated drug; 
‘‘(III) State, local, and Tribal govern-
ment officials and relevant agencies; 
‘‘(IV) communications professionals; 
‘‘(V) the public; and 
‘‘(VI) appropriate congressional com-
mittees. 
‘‘(iv) EVALUATION OF EFFECTIVENESS OF 
NATIONAL
MEDIA
CAMPAIGN.—In 
using 
amounts for the evaluation of the effectiveness 
of the national media campaign under subpara-
graph (A)(v), the Director shall—
587 
•HRES 1099 EH 
‘‘(I) designate an independent entity 
to evaluate by April 20 of each year the 
effectiveness of the national media cam-
paign based on data from— 
‘‘(aa) the Monitoring the Future 
Study published by the Department 
of Health and Human Services; 
‘‘(bb) the National Survey on 
Drug Use and Health; and 
‘‘(cc) other relevant studies or 
publications, as determined by the 
Director, including tracking and eval-
uation data collected according to 
marketing and advertising industry 
standards; and 
‘‘(II) ensure that the effectiveness of 
the national media campaign is evaluated 
in a manner that enables consideration of 
whether the national media campaign has 
contributed to changes in attitude or be-
haviors among the target audience with 
respect to substance use and such other 
measures of evaluation as the Director de-
termines are appropriate.
588 
•HRES 1099 EH 
‘‘(3) ADVERTISING.—In carrying out this sub-
section, the Director shall ensure that sufficient funds 
are allocated to meet the stated goals of the national 
media campaign. 
‘‘(4) RESPONSIBILITIES
AND
FUNCTIONS
UNDER 
THE PROGRAM.— 
‘‘(A) IN GENERAL.—The Director shall deter-
mine the overall purposes and strategy of the na-
tional media campaign. 
‘‘(B) DIRECTOR.— 
‘‘(i) IN GENERAL.—The Director shall ap-
prove— 
‘‘(I) the strategy of the national 
media campaign; 
‘‘(II) all advertising and promotional 
material used in the national media cam-
paign; and 
‘‘(III) the plan for the purchase of 
advertising time and space for the na-
tional media campaign. 
‘‘(ii) 
IMPLEMENTATION.—The 
Director 
shall be responsible for implementing a focused 
national media campaign to meet the purposes 
set forth in paragraph (1) and shall ensure—
589 
•HRES 1099 EH 
‘‘(I) 
information 
disseminated 
through the campaign is accurate and sci-
entifically valid; and 
‘‘(II) the campaign is designed using 
strategies demonstrated to be the most ef-
fective at achieving the goals and require-
ments of paragraph (1), which may in-
clude— 
‘‘(aa) a media campaign, as de-
scribed in paragraph (2); 
‘‘(bb) local, regional, or popu-
lation specific messaging; 
‘‘(cc) 
the 
development 
of 
websites to publicize and disseminate 
information; 
‘‘(dd) conducting outreach and 
providing educational resources for 
parents; 
‘‘(ee) collaborating with law en-
forcement agencies; and 
‘‘(ff) 
providing 
support 
for 
school-based public health education 
classes to improve teen knowledge 
about the effects of substance use.
590 
•HRES 1099 EH 
‘‘(5) PROHIBITIONS.—None of the amounts made 
available under paragraph (2) may be obligated or ex-
pended for any of the following: 
‘‘(A) To supplant current anti-drug commu-
nity-based coalitions. 
‘‘(B) To supplant pro bono public service time 
donated by national and local broadcasting net-
works for other public service campaigns. 
‘‘(C) For partisan political purposes, or to ex-
press advocacy in support of or to defeat any clearly 
identified candidate, clearly identified ballot initia-
tive, or clearly identified legislative or regulatory 
proposal. 
‘‘(D) To fund advertising that features any 
elected officials, persons seeking elected office, cabi-
net level officials, or other Federal officials em-
ployed pursuant to section 213 of Schedule C of 
title 5, Code of Federal Regulations. 
‘‘(E) To fund advertising that does not contain 
a primary message intended to reduce or prevent 
substance use. 
‘‘(F) To fund advertising containing a primary 
message intended to promote support for the na-
tional media campaign or private sector contribu-
tions to the national media campaign.
591 
•HRES 1099 EH 
‘‘(6) MATCHING REQUIREMENT.— 
‘‘(A) IN GENERAL.—Amounts made available 
under paragraph (2) for media time and space shall 
be matched by an equal amount of non-Federal 
funds for the national media campaign, or be 
matched with in-kind contributions of the same 
value. 
‘‘(B) NO-COST
MATCH
ADVERTISING
DIRECT 
RELATIONSHIP REQUIREMENT.—The Director shall 
ensure that not less than 85 percent of no-cost 
match advertising directly relates to substance 
abuse prevention consistent with the specific pur-
poses of the national media campaign. 
‘‘(C) NO-COST MATCH ADVERTISING NOT DI-
RECTLY RELATED.—The Director shall ensure that 
no-cost match advertising that does not directly re-
late to substance abuse prevention consistent with 
the purposes of the national media campaign in-
cludes a clear anti-drug message. Such message is 
not required to be the primary message of the 
match advertising. 
‘‘(7) FINANCIAL
AND
PERFORMANCE
ACCOUNT-
ABILITY.—The Director shall cause to be performed—
592 
•HRES 1099 EH 
‘‘(A) audits and reviews of costs of the national 
media campaign pursuant to section 4706 of title 
41, United States Code; and 
‘‘(B) an audit to determine whether the costs 
of the national media campaign are allowable under 
chapter 43 of title 41, United States Code. 
‘‘(8) REPORT TO CONGRESS.—The Director shall 
submit on an annual basis a report to Congress that de-
scribes— 
‘‘(A) the strategy of the national media cam-
paign and whether specific objectives of the national 
media campaign were accomplished; 
‘‘(B) steps taken to ensure that the national 
media campaign operates in an effective and effi-
cient manner consistent with the overall strategy 
and focus of the national media campaign; 
‘‘(C) plans to purchase advertising time and 
space; 
‘‘(D) policies and practices implemented to en-
sure that Federal funds are used responsibly to pur-
chase advertising time and space and eliminate the 
potential for waste, fraud, and abuse; 
‘‘(E) all contracts entered into with a corpora-
tion, partnership, or individual working on behalf of 
the national media campaign;
593 
•HRES 1099 EH 
‘‘(F) the results of any financial audit of the 
national media campaign; 
‘‘(G) a description of any evidence used to de-
velop the national media campaign; 
‘‘(H) specific policies and steps implemented to 
ensure compliance with this section; 
‘‘(I) a detailed accounting of the amount of 
funds obligated during the previous fiscal year for 
carrying out the national media campaign, including 
each recipient of funds, the purpose of each expend-
iture, the amount of each expenditure, any available 
outcome information, and any other information 
necessary to provide a complete accounting of the 
funds expended; and 
‘‘(J) a review and evaluation of the effective-
ness of the national media campaign strategy for 
the past year. 
‘‘(9) REQUIRED
NOTICE
FOR
COMMUNICATION 
FROM THE OFFICE.—Any communication, including an 
advertisement, paid for or otherwise disseminated by the 
Office directly or through a contract awarded by the Of-
fice shall include a prominent notice informing the audi-
ence that the communication was paid for by the Office. 
‘‘(g) AUTHORIZATION
OF APPROPRIATIONS.—There is 
authorized to be appropriated to the Office to carry out this
594 
•HRES 1099 EH 
section, $25,000,000 for each of fiscal years 2018 through 
2023.’’. 
(b) TECHNICAL AND CONFORMING AMENDMENT.—Sub-
section (a) of section 203 of the Office of National Drug Con-
trol Policy Reauthorization Act of 2006 (21 U.S.C. 1708a) 
is repealed. 
SEC. 8219. DRUG INTERDICTION. 
(a) REPEAL.—This first section 711 of the Office of Na-
tional Drug Control Policy Reauthorization Act of 1998 (21 
U.S.C. 1710) is repealed. 
(b) AMENDMENTS.—Section 711 of the Office of Na-
tional Drug Control Policy Reauthorization Act of 1998 (21 
U.S.C. 1710), as added by Public Law 109–469 (120 Stat. 
3507), is amended— 
(1) in subsection (a)— 
(A) in paragraph (1)— 
(i) by striking ‘‘The United’’ and inserting 
‘‘The Director shall designate or appoint an 
appointee in the Senior Executive Service or an 
appointee in a position at level 15 of the Gen-
eral Schedule (or equivalent) as the United’’; 
and 
(ii) by striking ‘‘shall’’ and inserting ‘‘to’’; 
(B) in paragraph (2)(B)—
595 
•HRES 1099 EH 
(i) by striking ‘‘March 1’’ and inserting 
‘‘September 1’’; and 
(ii) by striking ‘‘paragraph (3)’’ and in-
serting ‘‘paragraph (4)’’; 
(C) in paragraph (3)— 
(i) by striking ‘‘also, at his discretion,’’; 
and 
(ii) by striking ‘‘the Office of Supply Re-
duction for that purpose’’ and inserting ‘‘assist 
in carrying out such responsibilities’’; and 
(D) in paragraph (4)— 
(i) in subparagraph (B), by striking ‘‘The 
United’’ and inserting ‘‘Before submission of 
the National Drug Control Strategy or annual 
assessment required under section 706, as ap-
plicable, the United’’; 
(ii) by striking subparagraphs (C) and 
(E); 
(iii) by redesignating subparagraph (D) as 
subparagraph (C); 
(iv) in subparagraph (C), as so redesig-
nated— 
(I) in the matter preceding clause 
(i)—
596 
•HRES 1099 EH 
(aa) by striking ‘‘March 1’’ and 
inserting ‘‘September 1’’; 
(bb) by inserting ‘‘the Director, 
acting through’’ before ‘‘the United 
States’’; 
(cc) by inserting a comma after 
‘‘Coordinator’’; 
(dd) by striking ‘‘a report on be-
half of the Director’’; and 
(ee) by striking ‘‘, which shall 
include’’ and inserting ‘‘a report 
that’’; 
(II) by redesignating clauses (i), (ii), 
and (iii) as subclauses (I), (II), and (III), 
and adjusting the margins accordingly; 
(III) by inserting before subclause 
(I), as so redesignated, the following: 
‘‘(i) includes—’’; 
(IV) in clause (i), as so redesig-
nated— 
(aa) in subclause (I), as so re-
designated, by inserting ‘‘, including 
information about how each National 
Drug Control Program agency con-
ducting drug interdiction activities is
597 
•HRES 1099 EH 
engaging with relevant international 
partners’’ after ‘‘Plan’’; 
(bb) in subclause (II), as so re-
designated, by striking ‘‘, as well as’’ 
and inserting ‘‘and’’; 
(cc) in subclause III, as so re-
designated— 
(AA) by striking ‘‘, as well 
as’’ and inserting ‘‘and’’; and 
(BB) by striking the period 
at the end and inserting ‘‘; 
and’’; and 
(V) by adding at the end the fol-
lowing: 
‘‘(ii) may include recommendations for 
changes to existing agency authorities or laws 
governing interagency relationships.’’; and 
(v) by adding at the end the following: 
‘‘(D) CLASSIFIED
ANNEX.—Each report re-
quired to be submitted under subparagraph (C) 
shall be in unclassified form, but may include a 
classified annex.’’; 
(2) in subsection (b)— 
(A) in paragraph (1)(B), by inserting ‘‘and 
how to strengthen international partnerships to bet-
598 
•HRES 1099 EH 
ter achieve the goals of that plan’’ after ‘‘that 
plan’’; 
(B) in paragraph (2)— 
(i) in the paragraph heading, by striking 
‘‘CHAIRMAN’’ and inserting ‘‘CHAIRPERSON’’; 
and 
(ii) by striking ‘‘chairman’’ and inserting 
‘‘Chairperson’’; 
(C) in paragraph (3)— 
(i) by striking ‘‘prior to March 1’’ and in-
serting ‘‘before June 1’’; 
(ii) by striking ‘‘either’’ each place it ap-
pears; 
(iii) by striking ‘‘current chairman’’ and 
inserting ‘‘Chairperson’’; and 
(iv) by striking ‘‘they’’ and inserting ‘‘the 
members’’; and 
(D) in paragraph (4)— 
(i) by striking ‘‘chairman’’ each place it 
appears and inserting ‘‘Chairperson’’; 
(ii) in the first sentence, by striking ‘‘a re-
port’’; 
(iii) by inserting ‘‘a report’’ after ‘‘com-
mittees’’; and
599 
•HRES 1099 EH 
(iv) by striking the second sentence and 
inserting the following: ‘‘The report required 
under this paragraph shall be in unclassified 
form, but may include a classified annex.’’; and 
(3) by adding at the end the following: 
‘‘(c) INTERNATIONAL
COORDINATION.—The Director 
may facilitate international drug control coordination ef-
forts.’’. 
SEC. 8220. GAO AUDIT. 
Not later than 4 years after the date of enactment of 
this Act, and every 4 years thereafter, the Comptroller Gen-
eral of the United States shall— 
(1) conduct an audit relating to the programs and 
operations of— 
(A) the Office; and 
(B) certain programs within the Office, includ-
ing— 
(i) the High Intensity Drug Trafficking 
Areas Program; 
(ii) the Drug-Free Communities Program; 
and 
(iii) the campaign under section 709(f) of 
the Office of National Drug Control Policy Re-
authorization Act of 1998 (21 U.S.C. 1708(f)); 
and
600 
•HRES 1099 EH 
(2) submit to the Director and the appropriate con-
gressional committees a report containing an evaluation 
of and recommendations on the— 
(A) policies and activities of the programs and 
operations subject to the audit; 
(B) economy, efficiency, and effectiveness in 
the administration of the reviewed programs and 
operations; and 
(C) policy or management changes needed to 
prevent and detect fraud and abuse in such pro-
grams and operations. 
SEC. 8221. NATIONAL DRUG CONTROL STRATEGY. 
(a) IN GENERAL.—Section 706 of the Office of National 
Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 
1705) is amended to read as follows: 
‘‘SEC. 706. NATIONAL DRUG CONTROL STRATEGY. 
‘‘(a) IN GENERAL.— 
‘‘(1) STATEMENT OF DRUG POLICY PRIORITIES.— 
The Director shall release a statement of drug control 
policy priorities in the calendar year of a Presidential in-
auguration following the inauguration, but not later than 
April 1. 
‘‘(2) NATIONAL
DRUG
CONTROL
STRATEGY
SUB-
MITTED BY THE PRESIDENT.—Not later than the first 
Monday in February following the year in which the
601 
•HRES 1099 EH 
term of the President commences, and every 2 years 
thereafter, the President shall submit to Congress a Na-
tional Drug Control Strategy. 
‘‘(b) DEVELOPMENT OF THE NATIONAL DRUG CONTROL 
STRATEGY.— 
‘‘(1) PROMULGATION.—The Director shall promul-
gate the National Drug Control Strategy, which shall set 
forth a comprehensive plan to reduce illicit drug use and 
the consequences of such illicit drug use in the United 
States by limiting the availability of and reducing the 
demand for illegal drugs and promoting prevention, early 
intervention, treatment, and recovery support for individ-
uals with substance use disorders. 
‘‘(2) STATE AND LOCAL COMMITMENT.—The Direc-
tor shall seek the support and commitment of State, 
local, and Tribal officials in the formulation and imple-
mentation of the National Drug Control Strategy. 
‘‘(3) STRATEGY BASED ON EVIDENCE.—The Direc-
tor shall ensure the National Drug Control Strategy is 
based on the best available evidence regarding the poli-
cies that are most effective in reducing the demand for 
and supply of illegal drugs. 
‘‘(4) PROCESS FOR DEVELOPMENT AND SUBMISSION 
OF NATIONAL DRUG CONTROL STRATEGY.—In developing
602 
•HRES 1099 EH 
and effectively implementing the National Drug Control 
Strategy, the Director— 
‘‘(A) shall consult with— 
‘‘(i) the heads of the National Drug Con-
trol Program Agencies; 
‘‘(ii) each Coordinator listed in section 
704; 
‘‘(iii) the Interdiction Committee and the 
Emerging Threats Committee; 
‘‘(iv) the appropriate congressional com-
mittees and any other committee of jurisdic-
tion; 
‘‘(v) State, local, and Tribal officials; 
‘‘(vi) private citizens and organizations, 
including community and faith-based organiza-
tions, with experience and expertise in demand 
reduction; 
‘‘(vii) private citizens and organizations 
with experience and expertise in supply reduc-
tion; and 
‘‘(viii) appropriate representatives of for-
eign governments; and 
‘‘(B) in satisfying the requirements of subpara-
graph (A), shall ensure, to the maximum extent 
possible, that State, local, and Tribal officials and
603 
•HRES 1099 EH 
relevant private organizations commit to support 
and take steps to achieve the goals and objectives 
of the National Drug Control Strategy. 
‘‘(c) CONTENTS
OF
THE NATIONAL DRUG CONTROL 
STRATEGY.— 
‘‘(1) IN
GENERAL.—The National Drug Control 
Strategy submitted under subsection (a)(2) shall include 
the following: 
‘‘(A) A mission statement detailing the major 
functions of the National Drug Control Program. 
‘‘(B) Comprehensive, research-based, long- 
range, quantifiable goals for reducing illicit drug 
use, and the consequences of illicit drug use in the 
United States. 
‘‘(C) Annual quantifiable and measurable ob-
jectives and specific targets to accomplish long-term 
quantifiable goals that the Director determines may 
be achieved during each year beginning on the date 
on which the National Drug Control Strategy is 
submitted. 
‘‘(D) A 5-year projection for the National 
Drug Control Program and budget priorities. 
‘‘(E) A review of international, State, local, 
and private sector drug control activities to ensure
604 
•HRES 1099 EH 
that the United States pursues coordinated and ef-
fective drug control at all levels of government. 
‘‘(F) A description of how each goal estab-
lished under subparagraph (B) will be achieved, in-
cluding for each goal— 
‘‘(i) a list of each relevant National Drug 
Control Program Agency and each such agen-
cy’s related programs, activities, and available 
assets and the role of each such program, ac-
tivity, and asset in achieving such goal; 
‘‘(ii) a list of relevant stakeholders and 
each such stakeholder’s role in achieving such 
goal; 
‘‘(iii) an estimate of Federal funding and 
other resources needed to achieve such goal; 
‘‘(iv) a list of each existing or new coordi-
nating mechanism needed to achieve such goal; 
and 
‘‘(v) a description of the Office’s role in 
facilitating the achievement of such goal. 
‘‘(G) For each year covered by the Strategy, a 
performance evaluation plan for each goal estab-
lished under subparagraph (B) for each National 
Drug Control Program Agency, including—
605 
•HRES 1099 EH 
‘‘(i) specific performance measures for 
each National Drug Control Program Agency; 
‘‘(ii) annual and, to the extent practicable, 
quarterly objectives and targets for each per-
formance measure; and 
‘‘(iii) an estimate of Federal funding and 
other resources needed to achieve each per-
formance objective and target. 
‘‘(H) A list identifying existing data sources or 
a description of data collection needed to evaluate 
performance, including a description of how the Di-
rector will obtain such data. 
‘‘(I) A list of any anticipated challenges to 
achieving the National Drug Control Strategy goals 
and planned actions to address such challenges. 
‘‘(J) A description of how each goal established 
under subparagraph (B) was determined, includ-
ing— 
‘‘(i) a description of each required con-
sultation and a description of how such con-
sultation was incorporated; and 
‘‘(ii) data, research, or other information 
used to inform the determination to establish 
the goal.
606 
•HRES 1099 EH 
‘‘(K) A description of the current prevalence of 
illicit drug use in the United States, including both 
the availability of illicit drugs and the prevalence of 
substance use disorders. 
‘‘(L) Such other statistical data and informa-
tion as the Director considers appropriate to dem-
onstrate and assess trends relating to illicit drug 
use, the effects and consequences of illicit drug use 
(including the effects on children), supply reduction, 
demand reduction, drug-related law enforcement, 
and the implementation of the National Drug Con-
trol Strategy. 
‘‘(M) A systematic plan for increasing data col-
lection to enable real time surveillance of drug con-
trol threats, developing analysis and monitoring ca-
pabilities, and identifying and addressing policy 
questions related to the National Drug Control 
Strategy and Program, which shall include— 
‘‘(i) a list of policy-relevant questions for 
which the Director and each National Drug 
Control Program Agency intends to develop 
evidence to support the National Drug Control 
Program and Strategy; 
‘‘(ii) a list of data the Director and each 
National Drug Control Program Agency in-
607 
•HRES 1099 EH 
tends to collect, use, or acquire to facilitate the 
use of evidence in drug control policymaking 
and monitoring; 
‘‘(iii) a list of methods and analytical ap-
proaches that may be used to develop evidence 
to support the National Drug Control Program 
and Strategy and related policy; 
‘‘(iv) a list of any challenges to developing 
evidence to support policymaking, including 
any barriers to accessing, collecting, or using 
relevant data; 
‘‘(v) a description of the steps the Direc-
tor and the head of each National Drug Con-
trol Program Agency will take to effectuate the 
plan; and 
‘‘(vi) any other relevant information as de-
termined by the Director. 
‘‘(N) A plan to expand treatment of substance 
use disorders, which shall— 
‘‘(i) identify unmet needs for treatment 
for substance use disorders and a strategy for 
closing the gap between available and needed 
treatment;
608 
•HRES 1099 EH 
‘‘(ii) describe the specific roles and re-
sponsibilities of the relevant National Drug 
Control Programs for implementing the plan; 
‘‘(iii) identify the specific resources re-
quired to enable the relevant National Drug 
Control Agencies to implement that strategy; 
and 
‘‘(iv) identify the resources, including pri-
vate sources, required to eliminate the unmet 
need for evidence-based substance use disorder 
treatment. 
‘‘(2) CONSULTATION.—In developing the plan re-
quired under paragraph (1), the Director shall consult 
with the following: 
‘‘(A) The public. 
‘‘(B) Any evaluation or analysis units and per-
sonnel of the Office. 
‘‘(C) Office officials responsible for imple-
menting privacy policy. 
‘‘(D) Office officials responsible for data gov-
ernance. 
‘‘(E) The appropriate congressional commit-
tees. 
‘‘(F) Any other individual or entity as deter-
mined by the Director.
609 
•HRES 1099 EH 
‘‘(3) ADDITIONAL STRATEGIES.— 
‘‘(A) IN GENERAL.—The Director shall include 
in the National Drug Control Strategy the addi-
tional strategies described under this paragraph and 
shall comply with the following: 
‘‘(i) Provide a copy of the additional strat-
egies to the appropriate congressional commit-
tees and to the Committee on Armed Services 
and the Committee on Homeland Security of 
the House of Representatives, and the Com-
mittee on Homeland Security and Govern-
mental Affairs and the Committee on Armed 
Services of the Senate. 
‘‘(ii) Issue the additional strategies in con-
sultation with the head of each relevant Na-
tional Drug Control Program Agency, any rel-
evant official of a State, local, or Tribal gov-
ernment, and the government of other relevant 
countries. 
‘‘(iii) Not change any existing agency au-
thority or construe any strategy described 
under this paragraph to amend or modify any 
law governing interagency relationship but may 
include recommendations about changes to 
such authority or law.
610 
•HRES 1099 EH 
‘‘(iv) Present separately from the rest of 
any strategy described under this paragraph 
any information classified under criteria estab-
lished by an Executive order, or whose public 
disclosure, as determined by the Director or 
the head of any relevant National Drug Con-
trol Program Agency, would be detrimental to 
the law enforcement or national security activi-
ties of any Federal, State, local, or Tribal 
agency. 
‘‘(B) REQUIREMENT FOR SOUTHWEST BORDER 
COUNTERNARCOTICS STRATEGY.— 
‘‘(i) PURPOSES.—The Southwest Border 
Counternarcotics Strategy shall— 
‘‘(I) set forth the Government’s strat-
egy for preventing the illegal trafficking of 
drugs across the international border be-
tween the United States and Mexico, in-
cluding through ports of entry and be-
tween ports of entry on that border; 
‘‘(II) state the specific roles and re-
sponsibilities of the relevant National 
Drug Control Program Agencies for im-
plementing that strategy; and
611 
•HRES 1099 EH 
‘‘(III) identify the specific resources 
required to enable the relevant National 
Drug Control Program Agencies to imple-
ment that strategy. 
‘‘(ii) SPECIFIC
CONTENT
RELATED
TO 
DRUG
TUNNELS
BETWEEN
THE
UNITED 
STATES AND MEXICO.—The Southwest Border 
Counternarcotics Strategy shall include— 
‘‘(I) a strategy to end the construc-
tion and use of tunnels and subterranean 
passages that cross the international bor-
der between the United States and Mexico 
for the purpose of illegal trafficking of 
drugs across such border; and 
‘‘(II) recommendations for criminal 
penalties for persons who construct or use 
such a tunnel or subterranean passage for 
such a purpose. 
‘‘(C) REQUIREMENT FOR NORTHERN BORDER 
COUNTERNARCOTICS STRATEGY.— 
‘‘(i) PURPOSES.—The Northern Border 
Counternarcotics Strategy shall— 
‘‘(I) set forth the strategy of the Fed-
eral Government for preventing the illegal 
trafficking of drugs across the inter-
612 
•HRES 1099 EH 
national border between the United States 
and Canada, including through ports of 
entry and between ports of entry on the 
border; 
‘‘(II) state the specific roles and re-
sponsibilities of each relevant National 
Drug Control Program Agency for imple-
menting the strategy; 
‘‘(III) identify the specific resources 
required to enable the relevant National 
Drug Control Program Agencies to imple-
ment the strategy; 
‘‘(IV) be designed to promote, and 
not hinder, legitimate trade and travel; 
and 
‘‘(V) reflect the unique nature of 
small communities along the international 
border between the United States and 
Canada, ongoing cooperation and coordi-
nation with Canadian law, enforcement 
authorities, and variations in the volumes 
of 
vehicles 
and 
pedestrians 
crossing 
through ports of entry along the inter-
national border between the United States 
and Canada.
613 
•HRES 1099 EH 
‘‘(ii) SPECIFIC
CONTENT
RELATED
TO 
CROSS-BORDER
INDIAN
RESERVATIONS.—The 
Northern Border Counternarcotics Strategy 
shall include— 
‘‘(I) a strategy to end the illegal traf-
ficking of drugs to or through Indian res-
ervations on or near the international bor-
der between the United States and Can-
ada; and 
‘‘(II) recommendations for additional 
assistance, if any, needed by Tribal law 
enforcement agencies relating to the strat-
egy, including an evaluation of Federal 
technical and financial assistance, infra-
structure capacity building, and interoper-
ability deficiencies. 
‘‘(4) CLASSIFIED INFORMATION.—Any contents of 
the National Drug Control Strategy that involve infor-
mation properly classified under criteria established by 
an Executive order shall be presented to Congress sepa-
rately from the rest of the National Drug Control Strat-
egy. 
‘‘(5) SELECTION OF DATA AND INFORMATION.—In 
selecting data and information for inclusion in the Strat-
egy, the Director shall ensure—
614 
•HRES 1099 EH 
‘‘(A) the inclusion of data and information that 
will permit analysis of current trends against pre-
viously compiled data and information where the 
Director believes such analysis enhances long-term 
assessment of the National Drug Control Strategy; 
and 
‘‘(B) the inclusion of data and information to 
permit a standardized and uniform assessment of 
the effectiveness of drug treatment programs in the 
United States. 
‘‘(d) SUBMISSION OF REVISED STRATEGY.—The Presi-
dent may submit to Congress a revised National Drug Con-
trol Strategy that meets the requirements of this section— 
‘‘(1) at any time, upon a determination of the 
President, in consultation with the Director, that the 
National Drug Control Strategy in effect is not suffi-
ciently effective; or 
‘‘(2) if a new President or Director takes office. 
‘‘(e) FAILURE
OF DIRECTOR
TO SUBMIT NATIONAL 
DRUG CONTROL STRATEGY.—If the Director does not submit 
a National Drug Control Strategy to Congress in accordance 
with subsection (a)(2), not later than five days after the first 
Monday in February following the year in which the term of 
the President commences, the Director shall send a notifica-
tion to the appropriate congressional committees—
615 
•HRES 1099 EH 
‘‘(1) explaining why the Strategy was not sub-
mitted; and 
‘‘(2) specifying the date by which the Strategy will 
be submitted. 
‘‘(f) DRUG CONTROL DATA DASHBOARD.— 
‘‘(1) IN GENERAL.—The Director shall collect and 
disseminate, as appropriate, such information as the Di-
rector determines is appropriate, but not less than the 
information described in this subsection. The data shall 
be publicly available in a machine-readable format on the 
online portal of the Office, and to the extent practicable 
on the Drug Control Data Dashboard. 
‘‘(2) ESTABLISHMENT.—The Director shall publish 
to the online portal of the office in a machine-readable, 
sortable, and searchable format, or to the extent prac-
ticable, establish and maintain a data dashboard on the 
online portal of the Office to be known as the ‘Drug 
Control Data Dashboard’. To the extent practicable, 
when establishing the Drug Control Dashboard, the Di-
rector shall ensure the user interface of the dashboard 
is constructed with modern design standards. To the ex-
tent practicable, the data made available on the dash-
board shall be publicly available in a machine-readable 
format and searchable by year, agency, drug, and loca-
tion.
616 
•HRES 1099 EH 
‘‘(3) DATA.—The data included in the Drug Con-
trol Data Dashboard shall be updated quarterly to the 
extent practicable, but not less frequently than annually 
and shall include, at a minimum, the following: 
‘‘(A) For each substance identified by the Di-
rector as having a significant impact on the preva-
lence of illicit drug use— 
‘‘(i) data sufficient to show the quantities 
of such substance available in the United 
States, including— 
‘‘(I) the total amount seized and dis-
rupted in the calendar year and each of 
the previous 3 calendar years, including to 
the extent practicable the amount seized 
by State, local, and Tribal governments; 
‘‘(II) the known and estimated flows 
into the United States from all sources in 
the calendar year and each of the previous 
3 calendar years; 
‘‘(III) the total amount of known 
flows that could not be interdicted or dis-
rupted in the calendar year and each of 
the previous 3 calendar years; 
‘‘(IV) the known and estimated levels 
of domestic production in the calendar
617 
•HRES 1099 EH 
year and each of the previous three cal-
endar years, including the levels of domes-
tic production if the drug is a prescription 
drug, as determined under the Federal 
Food, Drug, and Cosmetic Act, for which 
a listing is in effect under section 202 of 
the Controlled Substances Act (21 U.S.C. 
812); 
‘‘(V) the average street price for the 
calendar year and the highest known 
street price during the preceding 10-year 
period; and 
‘‘(VI) to the extent practicable, re-
lated prosecutions by State, local, and 
Tribal governments; 
‘‘(ii) data sufficient to show the frequency 
of use of such substance, including— 
‘‘(I) use of such substance in the 
workplace and productivity lost by such 
use; 
‘‘(II) use of such substance by 
arrestees, probationers, and parolees; 
‘‘(III) crime and criminal activity re-
lated to such substance;
618 
•HRES 1099 EH 
‘‘(IV) to the extent practicable, re-
lated prosecutions by State, local, and 
Tribal governments; 
‘‘(B) For the calendar year and each of the 
previous three years data sufficient to show, 
disaggregated by State and, to the extent feasible, 
by region within a State, county, or city, the fol-
lowing: 
‘‘(i) The number of fatal and non-fatal 
overdoses caused by each drug identified under 
subparagraph (A)(i). 
‘‘(ii) The prevalence of substance use dis-
orders. 
‘‘(iii) The number of individuals who have 
received substance use disorder treatment, in-
cluding medication assisted treatment, for a 
substance use disorder, including treatment 
provided through publicly-financed health care 
programs. 
‘‘(iv) The extent of the unmet need for 
substance use disorder treatment, including the 
unmet need for medication-assisted treatment. 
‘‘(C) Data sufficient to show the extent of pre-
scription drug diversion, trafficking, and misuse in
619 
•HRES 1099 EH 
the calendar year and each of the previous 3 cal-
endar years. 
‘‘(D) Any quantifiable measures the Director 
determines to be appropriate to detail progress to-
ward the achievement of the goals of the National 
Drug Control Strategy. 
‘‘(g) DEVELOPMENT OF AN ANNUAL NATIONAL DRUG 
CONTROL ASSESSMENT.— 
‘‘(1) TIMING.—Not later than the first Monday in 
February of each year, the Director shall submit to the 
President, Congress, and the appropriate congressional 
committees, a report assessing the progress of each Na-
tional Drug Control Program Agency toward achieving 
each goal, objective, and target contained in the National 
Drug Control Strategy applicable to the prior fiscal year. 
‘‘(2) PROCESS FOR DEVELOPMENT OF THE ANNUAL 
ASSESSMENT.—Not later than November 1 of each year, 
the head of each National Drug Control Program Agen-
cy shall submit, in accordance with guidance issued by 
the Director, to the Director an evaluation of progress 
by the agency with respect to the National Drug Control 
Strategy goals using the performance measures for the 
agency developed under this title, including progress 
with respect to—
620 
•HRES 1099 EH 
‘‘(A) success in achieving the goals of the Na-
tional Drug Control Strategy; 
‘‘(B) success in reducing domestic and foreign 
sources of illegal drugs; 
‘‘(C) success in expanding access to and in-
creasing the effectiveness of substance use disorder 
treatment; 
‘‘(D) success in protecting the borders of the 
United States (and in particular the Southwestern 
border of the United States) from penetration by il-
legal narcotics; 
‘‘(E) success in reducing crime associated with 
drug use in the United States; 
‘‘(F) success in reducing the negative health 
and social consequences of drug use in the United 
States; 
‘‘(G) implementation of evidence-based sub-
stance use disorder treatment and prevention pro-
grams in the United States and improvements in 
the adequacy and effectiveness of such programs; 
and 
‘‘(H) success in increasing the prevention of il-
licit drug use.
621 
•HRES 1099 EH 
‘‘(3) CONTENTS OF THE ANNUAL ASSESSMENT.— 
The Director shall include in the annual assessment re-
quired under paragraph (1)— 
‘‘(A) a summary of each evaluation received by 
the Director under paragraph (2); 
‘‘(B) a summary of the progress of each Na-
tional Drug Control Program Agency toward the 
National Drug Control Strategy goals of the agency 
using the performance measures for the agency de-
veloped under this chapter; 
‘‘(C) an assessment of the effectiveness of each 
National Drug Control Program Agency and pro-
gram in achieving the National Drug Control Strat-
egy for the previous year, including a specific eval-
uation of whether the applicable goals, measures, 
objectives, and targets for the previous year were 
met; and 
‘‘(D) the assessments required under this sub-
section shall be based on the Performance Measure-
ment System.’’. 
(b) TECHNICAL AND CONFORMING AMENDMENTS.— 
(1) Section 704(b) of the Office of National Drug 
Control Policy Reauthorization Act of 1998 (21 U.S.C. 
1703(b)) is amended— 
(A) by striking paragraphs (13) and (17); and
622 
•HRES 1099 EH 
(B) in paragraph (14)(A), by striking ‘‘para-
graph (13)’’ and inserting ‘‘section 706(g)(2)’’. 
(2) The Office of National Drug Control Policy Re-
authorization Act of 2006 (Public Law 109–469; 120 
Stat. 3502) is amended by striking sections 1110 and 
1110A. 
SEC. 8222. TECHNICAL AND CONFORMING AMENDMENTS TO 
THE OFFICE OF NATIONAL DRUG CONTROL POL-
ICY REAUTHORIZATION ACT OF 1998. 
The Office of National Drug Control Policy Reauthoriza-
tion Act of 1998 (21 U.S.C. 1701 et seq.) is amended— 
(1) by striking section 703(b) (21 U.S.C. 1702(b)); 
(2) in section 704 (21 U.S.C. 1703)— 
(A) in subsection (c)— 
(i) in paragraph (3)(C)— 
(I) in the matter before clause (i), by 
inserting ‘‘requests a level of funding that 
will not enable achievement of the goals of 
the National Drug Control Strategy, in-
cluding’’ after ‘‘request that’’; 
(II) in clause (iii)— 
(aa) by striking ‘‘drug treat-
ment’’ and inserting ‘‘substance use 
disorder prevention and treatment’’; 
and
623 
•HRES 1099 EH 
(bb) by striking the semicolon at 
the end and inserting ‘‘; and’’; 
(III) by striking clauses (iv), (vi), and 
(vii); 
(IV) by redesignating clause (v) as 
clause (iv); and 
(V) in clause (iv), as so redesignated, 
by striking the semicolon and inserting a 
period; 
(ii) in paragraph (4)(A), by striking 
‘‘$1,000,000’’ and inserting ‘‘$5,000,000 or 10 
percent of a specific program or account’’; and 
(B) in subsection (f)— 
(i) by striking the first paragraph (5); and 
(ii) by striking the second paragraph (4); 
and 
(3) by striking section 708 (21 U.S.C. 1707). 
Subtitle L—Budgetary Effects 
SEC. 8231. BUDGETARY EFFECT. 
(a) IN GENERAL.—The budgetary effects of this Act 
shall not be entered on either PAYGO scorecard maintained 
pursuant to section 4(d) of the Statutory Pay-As-You-Go Act 
of 2010 (2 U.S.C. 933(d)). 
(b) SENATE PAYGO SCORECARDS.—The budgetary ef-
fects of this Act shall not be entered on any PAYGO score-
624 
•HRES 1099 EH 
card maintained for purposes of section 4106 of H. Con. Res. 
71 (115th Congress). 
Attest: 
Clerk.